



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

10 January 2022
EMA/PRAC/13739/2022
Human Medicines Division

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 10-13 January 2022

Chair: Sabine Straus – Vice-Chair: Martin Huber

10 January 2022, 10:30 – 19:30, via teleconference

11 January 2022, 08:30 – 19:30, via teleconference

12 January 2022, 08:30 – 19:30, via teleconference

13 January 2022, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)

27 January 2022, 09:00 – 12:00, via teleconference

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents ([EMA/127362/2006, Rev. 1](#)).



Table of contents

1.	Introduction	13
1.1.	Welcome and declarations of interest of members, alternates and experts	13
1.2.	Agenda of the meeting on 10-13 January 2022	13
1.3.	Minutes of the previous meeting on 29 November - 02 December 2021	13
2.	EU referral procedures for safety reasons: urgent EU procedures	13
2.1.	Newly triggered procedures	13
2.2.	Ongoing procedures	13
2.3.	Procedures for finalisation.....	13
3.	EU referral procedures for safety reasons: other EU referral procedures	13
3.1.	Newly triggered procedures	13
3.1.1.	Terlipressin (NAP) - EMEA/H/A31/1514	13
3.2.	Ongoing procedures	14
3.3.	Procedures for finalisation.....	14
3.4.	Re-examination procedures.....	14
3.5.	Others	14
4.	Signals assessment and prioritisation	14
4.1.	New signals detected from EU spontaneous reporting systems	14
4.1.1.	Calcitonin gene-related peptide (CGRP) antagonists: eptinezumab – VYEPTI, erenumab – AIMOVIG (CAP), fremanezumab – AJOVY (CAP), galcanezumab – EMGALITY (CAP)	14
4.1.2.	Osimertinib – TAGRISSO (CAP)	15
4.1.3.	Roxadustat – EVRENZO (CAP)	15
4.2.	New signals detected from other sources	15
4.2.1.	Human normal immunoglobulin – FLEBOGAMMA DIF (CAP), KIOVIG (CAP), PRIVIGEN (CAP); NAP	15
4.3.	Signals follow-up and prioritisation	15
4.3.1.	Durvalumab – IMFINZI (CAP) - EMEA/H/C/004771/SDA/009.....	15
4.3.2.	Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/SDA/052	16
4.3.3.	Pregabalin – LYRICA (CAP); NAP - EMEA/H/C/000546/SDA/055	16
4.3.4.	Tocilizumab – ROACTEMRA (CAP) - EMEA/H/C/000955/SDA/059	16
4.4.	Variation procedure(s) resulting from signal evaluation	16
4.4.1.	Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/II/0055.....	16
5.	Risk management plans (RMPs)	17
5.1.	Medicines in the pre-authorisation phase	17

5.1.1.	Amifampridine - EMEA/H/C/005839	17
5.1.2.	Budesonide, micronised - EMEA/H/C/005653, Orphan	17
5.1.3.	Capmatinib - EMEA/H/C/004845.....	17
5.1.4.	Dimethyl fumarate - EMEA/H/C/006039	17
5.1.5.	Dimethyl fumarate - EMEA/H/C/005956	17
5.1.6.	Dimethyl fumarate - EMEA/H/C/005955	17
5.1.7.	Dimethyl fumarate - EMEA/H/C/006042	17
5.1.8.	Ganaxolone - EMEA/H/C/005825, Orphan.....	18
5.1.9.	Insulin aspart - EMEA/H/C/005635	18
5.1.10.	Leuprorelin - EMEA/H/C/005034.....	18
5.1.11.	Mosunetuzumab - EMEA/H/C/005680, Orphan	18
5.1.12.	PF-07321332, ritonavir - EMEA/H/C/005973	18
5.2.	Medicines in the post-authorisation phase – PRAC-led procedures.....	18
5.2.1.	Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/II/0011	18
5.2.2.	Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/II/0029.....	19
5.2.3.	Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0020.....	19
5.2.4.	Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/II/0026, Orphan	19
5.2.5.	Mercaptamine - CYSTADROPS (CAP) - EMEA/H/C/003769/II/0023, Orphan	20
5.2.6.	Nintedanib - OFEV (CAP) - EMEA/H/C/003821/II/0046	20
5.2.7.	Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/WS2185/0041; NEPARVIS (CAP) - EMEA/H/C/004343/WS2185/0039	20
5.2.8.	Temozolomide - TEMODAL (CAP) - EMEA/H/C/000229/II/0095.....	21
5.2.9.	Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0087	21
5.3.	Medicines in the post-authorisation phase – CHMP-led procedures	21
5.3.1.	Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/II/0038	21
5.3.2.	Brigatinib - ALUNBRIG (CAP) - EMEA/H/C/004248/II/0037	21
5.3.3.	Brivaracetam - BRIVIACT (CAP) - EMEA/H/C/003898/II/0032/G.....	22
5.3.4.	Caplacizumab - CABLIVI (CAP) - EMEA/H/C/004426/II/0035, Orphan	22
5.3.5.	Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/II/0020	22
5.3.6.	Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/II/0053, Orphan.....	23
5.3.7.	Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0069/G	23
5.3.8.	Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0073	23
5.3.9.	Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0027	24
5.3.10.	Eptacog alfa (activated) - NOVOSEVEN (CAP) - EMEA/H/C/000074/II/0116	24
5.3.11.	Etanercept - ENBREL (CAP) - EMEA/H/C/000262/II/0246	24
5.3.12.	Galsulfase - NAGLAZYME (CAP) - EMEA/H/C/000640/II/0086.....	24
5.3.13.	Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/II/0006, PRIME, Orphan.....	25
5.3.14.	Guselkumab - TREMFYA (CAP) - EMEA/H/C/004271/II/0031	25

5.3.15.	Ibrutinib - IMBRUVICA (CAP) - EMEA/H/C/003791/II/0069	25
5.3.16.	Idecabtagene vicleucel - ABECMA (CAP) - EMEA/H/C/004662/II/0010, PRIME, Orphan.....	25
5.3.17.	Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/WS2049/0009/G; VIMPAT (CAP) - EMEA/H/C/000863/WS2049/0091/G	26
5.3.18.	Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/II/0009, Orphan.....	26
5.3.19.	Olaparib - LYNPARZA (CAP) - EMEA/H/C/003726/II/0051/G.....	26
5.3.20.	Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0117	27
5.3.21.	Ponatinib - ICLUSIG (CAP) - EMEA/H/C/002695/II/0061, Orphan	27
5.3.22.	Secukinumab - COSENTYX (CAP) - EMEA/H/C/003729/II/0079	27
5.3.23.	Semaglutide - OZEMPIC (CAP) - EMEA/H/C/004174/WS2141/0024; RYBELSUS (CAP) - EMEA/H/C/004953/WS2141/0018	27
5.3.24.	Setmelanotide - IMCIVREE (CAP) - EMEA/H/C/005089/II/0002/G, PRIME, Orphan.....	28
5.3.25.	Tagraxofusp - ELZONRIS (CAP) - EMEA/H/C/005031/II/0009, Orphan	28
5.3.26.	Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/II/0012	28
5.3.27.	Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/X/0012/G.....	29

6. Periodic safety update reports (PSURs) 29

6.1.	PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only	29
6.1.1.	Afamelanotide - SCENESSE (CAP) - PSUSA/00010314/202106.....	29
6.1.2.	Alpelisib - PIQRAY (CAP) - PSUSA/00010871/202105.....	29
6.1.3.	Angiotensin II - GIAPREZA (CAP) - PSUSA/00010785/202106.....	29
6.1.4.	Atidarsagene autotemcel - LIBMELDY (CAP) - PSUSA/00010899/202106.....	30
6.1.5.	Azacitidine - VIDAZA (CAP) - PSUSA/00000274/202105.....	30
6.1.6.	Berotrastat - ORLADEYO (CAP) - PSUSA/00010930/202106	30
6.1.7.	Betibeglogene autotemcel - ZYNTEGLO (CAP) - PSUSA/00010769/202105	30
6.1.8.	Binimetinib - MEKTOVI (CAP) - PSUSA/00010717/202106	30
6.1.9.	Bromfenac - YELLOX (CAP) - PSUSA/00000436/202105	31
6.1.10.	Buprenorphine - SIXMO (CAP) - PSUSA/00010778/202105.....	31
6.1.11.	Cannabidiol - EPIDYOLEX (CAP) - PSUSA/00010798/202106.....	31
6.1.12.	Cholera vaccine, oral, live - VAXCHORA (CAP) - PSUSA/00010862/202106.....	31
6.1.13.	Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - PSUSA/00010897/202106	31
6.1.14.	Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - PSUSA/00010912/202106	32
6.1.15.	Crisaborole - STAQUIS (CAP) - PSUSA/00010842/202106	32
6.1.16.	Dasatinib - SPRYCEL (CAP) - PSUSA/00000935/202106	32
6.1.17.	Delafloxacin - QUOFENIX (CAP) - PSUSA/00010822/202106	32
6.1.18.	Dengue tetravalent vaccine (live, attenuated) - DENGIVAXIA (CAP) - PSUSA/00010740/202106	32
6.1.19.	Efmoroctocog alfa - ELOCTA (CAP) - PSUSA/00010451/202106.....	32

6.1.20.	Encorafenib - BRAFTOVI (CAP) - PSUSA/00010719/202106	33
6.1.21.	Entrectinib - ROZLYTREK (CAP) - PSUSA/00010874/202106	33
6.1.22.	Fenfluramine - FINTEPLA (CAP) - PSUSA/00010907/202106	33
6.1.23.	Fluticasone furoate, vilanterol - RELVAR ELLIPTA (CAP); REVINTY ELLIPTA (CAP) - PSUSA/00010099/202105	33
6.1.24.	Formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - TRIKEO AEROSPHERE (CAP) - PSUSA/00010908/202106	33
6.1.25.	Galsulfase - NAGLAZYME (CAP) - PSUSA/00001515/202105	34
6.1.26.	Glibenclamide - AMGLIDIA (CAP) - PSUSA/00010690/202105	34
6.1.27.	Human papillomavirus 9-valent vaccine (recombinant, adsorbed) - GARDASIL 9 (CAP) - PSUSA/00010389/202106	34
6.1.28.	Hydroxycarbamide - SIKLOS (CAP); XROMI (CAP) - PSUSA/00001692/202106	34
6.1.29.	Imiglucerase - CERESZYME (CAP) - PSUSA/00001727/202105.....	34
6.1.30.	Inclisiran - LEQVIO (CAP) - PSUSA/00010904/202106	34
6.1.31.	Indacaterol, mometasone furoate - ATECTURA BREEZHALER (CAP); BEMRIST BREEZHALER (CAP) - PSUSA/00010850/202105	35
6.1.32.	Interferon beta-1a - AVONEX (CAP) - PSUSA/00010725/202105	35
6.1.33.	Interferon beta-1a - REBIF (CAP) - PSUSA/00010726/202105.....	35
6.1.34.	Larotrectinib - VITRAKVI (CAP) - PSUSA/00010799/202105.....	35
6.1.35.	Latanoprost, netarsudil - ROCLANDA (CAP) - PSUSA/00010905/202106.....	35
6.1.36.	Levodopa - INBRIJA (CAP) - PSUSA/00107800/202106	36
6.1.37.	Linagliptin - TRAJENTA (CAP); linagliptin, metformin - JENTADUETO (CAP) - PSUSA/00010427/202105	36
6.1.38.	Luspatercept - REBLOZYL (CAP) - PSUSA/00010860/202106	36
6.1.39.	Migalastat - GALAFOLD (CAP) - PSUSA/00010507/202105.....	36
6.1.40.	Netarsudil - RHOKIINSA (CAP) - PSUSA/00107812/202106	36
6.1.41.	Nevirapine - VIRAMUNE (CAP) - PSUSA/00002147/202105.....	36
6.1.42.	Nonacog beta pegol - REFIXIA (CAP) - PSUSA/00010608/202105.....	37
6.1.43.	Nusinersen - SPINRAZA (CAP) - PSUSA/00010595/202105.....	37
6.1.44.	Obeticholic acid - OCALIVA (CAP) - PSUSA/00010555/202105	37
6.1.45.	Onasemnogene abeparvovec - ZOLGENSMA (CAP) - PSUSA/00010848/202105.....	37
6.1.46.	Opicapone - ONGENTYS (CAP) - PSUSA/00010516/202106.....	37
6.1.47.	Palivizumab - SYNAGIS (CAP) - PSUSA/00002267/202106	38
6.1.48.	Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - ADJUPANRIX (CAP) - PSUSA/00002281/202105	38
6.1.49.	Pegvaliase - PALYNZIQ (CAP) - PSUSA/00010761/202105	38
6.1.50.	Pentosan polysulfate sodium - ELMIRON (CAP) - PSUSA/00010614/202106.....	38
6.1.51.	Pertuzumab - PERJETA (CAP) - PSUSA/00010125/202106	38
6.1.52.	Pertuzumab, trastuzumab - PHESGO (CAP) - PSUSA/00010906/202106.....	38
6.1.53.	Polatuzumab vedotin - POLIVY (CAP) - PSUSA/00010817/202106	39
6.1.54.	Propranolol - HEMANGIOL (CAP) - PSUSA/00010250/202104.....	39

6.1.55.	Ravulizumab - ULTOMIRIS (CAP) - PSUSA/00010787/202106	39
6.1.56.	Rilpivirine - EDURANT (CAP) - PSUSA/00009282/202105.....	39
6.1.57.	Semaglutide - OZEMPIC (CAP); RYBELSUS (CAP) - PSUSA/00010671/202105.....	39
6.1.58.	Sildenafil - REVATIO (CAP) - PSUSA/00002700/202105.....	40
6.1.59.	Sofosbuvir, velpatasvir - EPCLUSA (CAP) - PSUSA/00010524/202106	40
6.1.60.	Sonidegib - ODOMZO (CAP) - PSUSA/00010408/202106	40
6.1.61.	Tozinameran - COMIRNATY (CAP) - PSUSA/00010898/202106.....	40
6.1.62.	Trametinib - MEKINIST (CAP) - PSUSA/00010262/202105.....	40
6.1.63.	Trastuzumab deruxtecan - ENHERTU (CAP) - PSUSA/00010894/202106.....	40
6.1.64.	Treosulfan - TRECONDI (CAP) - PSUSA/00010777/202106	41
6.1.65.	Turoctocog alfa pegol - ESPEROCT (CAP) - PSUSA/00010782/202106	41
6.2.	PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)	41
6.2.1.	Capsaicin - QUTENZA (CAP); NAP - PSUSA/00000533/202105	41
6.2.2.	Imatinib - GLIVEC (CAP); NAP - PSUSA/00001725/202105.....	41
6.2.3.	Measles, mumps, rubella vaccines (live, attenuated) - M-M-RVAXPRO (CAP); NAP - PSUSA/00001937/202105	41
6.2.4.	Treprostinil - TREPULMIX (CAP); NAP - PSUSA/00003013/202105	42
6.3.	PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only	42
6.3.1.	5 fluorouracil, salicylic acid (NAP) - PSUSA/00000008/202105	42
6.3.2.	Acipimox (NAP) - PSUSA/00000050/202105	42
6.3.3.	Amino acid combinations, glucose, triglyceride combinations, with or without electrolytes, mineral compounds (NAP) - PSUSA/00010565/202106.....	42
6.3.4.	Amino acid combinations, glucose, with or without electrolytes, mineral compounds (NAP) - PSUSA/00010566/202106	43
6.3.5.	Benazepril, hydrochlorothiazide (NAP) - PSUSA/00000314/202105	43
6.3.6.	Bismuth subcitrate potassium, metronidazole, tetracycline (NAP) - PSUSA/00010199/202105	43
6.3.7.	Cidofovir (NAP) - PSUSA/00010558/202106.....	43
6.3.8.	Clevidipine (NAP) - PSUSA/00010288/202105.....	43
6.3.9.	Daunorubicin (NAP) - PSUSA/00000936/202106	43
6.3.10.	Flunarizine (NAP) - PSUSA/00001416/202105.....	44
6.3.11.	Goserelin (NAP) - PSUSA/00001562/202105.....	44
6.3.12.	Human hemin (NAP) - PSUSA/00001629/202105	44
6.3.13.	Iodine (¹³¹ I) iobenguane (NAP) - PSUSA/00001764/202105.....	44
6.3.14.	Lactulose (NAP) - PSUSA/00001821/202105.....	44
6.3.15.	Lanreotide (NAP) - PSUSA/00001826/202105	45
6.3.16.	Levofloxacin, dexamethasone (NAP) - PSUSA/00010881/202106.....	45
6.3.17.	Levonorgestrel (NAP) - PSUSA/00010828/202105	45
6.3.18.	Loperamide (NAP); loperamide, simeticone (NAP) - PSUSA/00010665/202105.....	45

6.3.19.	Milnacipran (NAP) - PSUSA/00002063/202104	45
6.3.20.	Misoprostol (NAP) - PSUSA/00010291/202106	45
6.3.21.	Misoprostol (NAP) - PSUSA/00010353/202105	46
6.3.22.	Moxifloxacin (NAP) - PSUSA/00002094/202105	46
6.3.23.	Nadifloxacin (NAP) - PSUSA/00002102/202105	46
6.3.24.	Olodaterol, tiotropium (NAP) - PSUSA/00010489/202105	46
6.3.25.	Pamidronate (NAP) - PSUSA/00002269/202105	46
6.3.26.	Paracetamol (NAP) - PSUSA/00002311/202105	47
6.3.27.	Phenylpropanolamine (NAP) - PSUSA/00010483/202106	47
6.3.28.	Pholcodine (NAP) - PSUSA/00002396/202105	47
6.3.29.	Ranitidine (NAP) - PSUSA/00002610/202105	47
6.3.30.	Remifentanil (NAP) - PSUSA/00002617/202105	47
6.3.31.	Triglyceride combinations, with or without mineral compounds, electrolytes (NAP) - PSUSA/00010648/202106	47
6.4.	Follow-up to PSUR/PSUSA procedures	48
6.4.1.	Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/LEG 056.....	48
6.4.2.	Pregabalin - PREGABALIN PFIZER (CAP) - EMEA/H/C/003880/LEG 008.....	48
6.4.3.	Tenofovir disoproxil - VIREAD (CAP) - EMEA/H/C/000419/LEG 278	48
6.5.	Variation procedure(s) resulting from PSUSA evaluation	48
6.5.1.	Arsenic trioxide - TRISENOX (CAP) - EMEA/H/C/000388/II/0076	48
6.5.2.	Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/II/0031.....	49
6.5.3.	Clofarabine - EVOLTRA (CAP) - EMEA/H/C/000613/II/0075.....	49
6.5.4.	Coronavirus (COVID-19) vaccine (Ad26.COVID-19, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/II/0035.....	49
6.5.5.	Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0025	50
6.5.6.	Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0080	50
6.6.	Expedited summary safety reviews	50
6.6.1.	Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 027.7	50

7.	Post-authorisation safety studies (PASS)	51
-----------	---	-----------

7.1.	Protocols of PASS imposed in the marketing authorisation(s).....	51
7.1.1.	Lenalidomide - REVLIMID (CAP) - EMEA/H/C/PSA/S/0075.1.....	51
7.1.2.	Parathyroid hormone – NATPAR (CAP) - EMEA/H/C/PSA/S/0053.4	51
7.1.3.	Selumetinib - KOSELUGO (CAP) - EMEA/H/C/PSP/S/0095.1	51
7.1.4.	Tisagenlecleucel - KYMRIAH (CAP) - EMEA/H/C/PSA/S/0080	51
7.1.5.	Valproate (NAP) - EMEA/H/N/PSP/J/0074.4.....	52
7.1.6.	Valproate (NAP) - EMEA/H/N/PSA/J/0077	52
7.1.7.	Voretigene neparvovec - LUXTURNA (CAP) - EMEA/H/C/PSA/S/0081.....	52
7.2.	Protocols of PASS non-imposed in the marketing authorisation(s)	53

7.2.1.	Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/MEA 003.1	53
7.2.2.	Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 004.2	53
7.2.3.	Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 005.2	53
7.2.4.	Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 006.2	53
7.2.5.	Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 004.4	54
7.2.6.	Isatuximab - SARCLISA (CAP) - EMEA/H/C/004977/MEA 002.2	54
7.2.7.	Patisiran - ONPATTRO (CAP) - EMEA/H/C/004699/MEA 003.2.....	54
7.2.8.	Ponesimod - PONVORY (CAP) - EMEA/H/C/005163/MEA 001	55
7.2.9.	Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 001.4	55
7.2.10.	Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 002.7	55
7.2.11.	Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 002.4.....	55
7.2.12.	Somapacitan - SOGROYA (CAP) - EMEA/H/C/005030/MEA 002.1	56
7.2.13.	Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/MEA 003.1	56
7.3.	Results of PASS imposed in the marketing authorisation(s).....	56
7.3.1.	Hydroxyethyl starch (HES) (NAP) - EMEA/H/N/PSR/J/0031	56
7.4.	Results of PASS non-imposed in the marketing authorisation(s).....	57
7.4.1.	Apremilast - OTEZLA (CAP) - EMEA/H/C/003746/II/0039	57
7.4.2.	Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0028	57
7.4.3.	Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0231.....	57
7.4.4.	Influenza vaccine surface antigen inactivated prepared in cell cultures - FLUCELVAX TETRA (CAP) - EMEA/H/C/004814/II/0023.....	57
7.4.5.	Insulin glargine, lixisenatide - SULIQUA (CAP) - EMEA/H/C/004243/II/0024	58
7.4.6.	Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0034	58
7.4.7.	Susoctocog alfa - OBIZUR (CAP) - EMEA/H/C/002792/II/0043	58
7.4.8.	Teriflunomide - AUBAGIO (CAP) - EMEA/H/C/002514/II/0038	58
7.4.9.	Trastuzumab - ONTRUZANT (CAP) - EMEA/H/C/004323/II/0036.....	59
7.5.	Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation.....	59
7.5.1.	Acidinium - BRETARIS GENUAIR (CAP) - EMEA/H/C/002706/ANX 001.10.....	59
7.5.2.	Acidinium - EKLIRA GENUAIR (CAP) - EMEA/H/C/002211/ANX 001.10.....	59
7.5.3.	Acidinium, formoterol fumarate dihydrate - BRIMICA GENUAIR (CAP) - EMEA/H/C/003969/ANX 003.7.....	60
7.5.4.	Acidinium, formoterol fumarate dihydrate - DUAKLIR GENUAIR (CAP) - EMEA/H/C/003745/ANX 003.7.....	60
7.5.5.	Burosumab - CRYSVITA (CAP) - EMEA/H/C/004275/MEA 004.3	60
7.5.6.	Cangrelor - KENGREXAL (CAP) - EMEA/H/C/003773/MEA 002.4.....	60
7.5.7.	Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/MEA 002.2.....	61
7.5.8.	Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 005.2	61

7.5.9.	Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 006.2	61
7.5.10.	Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 007.3	61
7.5.11.	Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 003.4	62
7.5.12.	Ketoconazole - KETOCONAZOLE HRA (CAP) - EMEA/H/C/003906/ANX 002.8.....	62
7.5.13.	Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.3	62
7.5.14.	Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.3	62
7.5.15.	Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.2	63
7.5.16.	Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 004.11	63
7.5.17.	Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 003.8.....	63
7.5.18.	Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 045.7	63
7.6.	Others	64
7.6.1.	Cabazitaxel - CABAZITAXEL ACCORD (CAP) - EMEA/H/C/005178/MEA 001.1	64
7.6.2.	Fentanyl - INSTANYL (CAP) - EMEA/H/C/000959/LEG 028.4.....	64
7.6.3.	Insulin human - INSUMAN (CAP) - EMEA/H/C/000201/MEA 041.5	64
7.6.4.	Lopinavir, ritonavir - KALETRA (CAP) - EMEA/H/C/000368/LEG 121.4	64
7.7.	New Scientific Advice	65
7.8.	Ongoing Scientific Advice	65
7.9.	Final Scientific Advice (Reports and Scientific Advice letters)	65

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 65

8.1.	Annual reassessments of the marketing authorisation	65
8.1.1.	Idebenone - RAXONE (CAP) - EMEA/H/C/003834/S/0029 (with RMP)	65
8.1.2.	Metreleptin - MYALEPTA (CAP) - EMEA/H/C/004218/S/0023 (without RMP).....	65
8.2.	Conditional renewals of the marketing authorisation	65
8.2.1.	Andexanet alfa - ONDEXXYA (CAP) - EMEA/H/C/004108/R/0025 (without RMP)	65
8.2.2.	Bosutinib - BOSULIF (CAP) - EMEA/H/C/002373/R/0051 (without RMP).....	66
8.2.3.	Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/R/0052 (without RMP)	66
8.2.4.	Lorlatinib - LORVIQUA (CAP) - EMEA/H/C/004646/R/0019 (without RMP)	66
8.2.5.	Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - PANDEMIC INFLUENZA VACCINE H5N1 ASTRAZENECA (CAP) - EMEA/H/C/003963/R/0047 (without RMP).....	66
8.2.6.	Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/R/0030 (without RMP).....	66
8.3.	Renewals of the marketing authorisation	67
8.3.1.	Beclometasone, formoterol, glycopyrronium bromide - TRIMBOW (CAP) - EMEA/H/C/004257/R/0025 (without RMP)	67
8.3.2.	Brodalumab - KYNTHEUM (CAP) - EMEA/H/C/003959/R/0019 (with RMP)	67
8.3.3.	Carglumic acid - UCEDANE (CAP) - EMEA/H/C/004019/R/0011 (without RMP).....	67
8.3.4.	Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/R/0026 (with RMP)	67

8.3.5.	Cenegermis - OXERVATE (CAP) - EMEA/H/C/004209/R/0037 (with RMP).....	67
8.3.6.	Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/R/0034 (without RMP)	67
8.3.7.	Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/R/0053 (with RMP)	68
8.3.8.	Efavirenz, emtricitabine, tenofovir disoproxil - EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP) - EMEA/H/C/004250/R/0025 (without RMP)	68
8.3.9.	Etanercept - ERELZI (CAP) - EMEA/H/C/004192/R/0037 (with RMP)	68
8.3.10.	Glecaprevir, pibrentasvir - MAVIRET (CAP) - EMEA/H/C/004430/R/0048 (without RMP)	68
8.3.11.	Insulin lispro - INSULIN LISPRO SANOFI (CAP) - EMEA/H/C/004303/R/0013 (with RMP) ..	68
8.3.12.	Osimertinib - TAGRISSO (CAP) - EMEA/H/C/004124/R/0044 (with RMP).....	69
8.3.13.	Patiromer - VELTASSA (CAP) - EMEA/H/C/004180/R/0028 (without RMP).....	69
8.3.14.	Ribociclib - KISQALI (CAP) - EMEA/H/C/004213/R/0034 (without RMP)	69

9. Product related pharmacovigilance inspections 69

9.1.	List of planned pharmacovigilance inspections.....	69
9.2.	Ongoing or concluded pharmacovigilance inspections.....	69
9.3.	Others	69

10. Other safety issues for discussion requested by the CHMP or the EMA 70

10.1.	Safety related variations of the marketing authorisation.....	70
10.2.	Timing and message content in relation to Member States' safety announcements	70
10.3.	Other requests.....	70
10.4.	Scientific Advice	70

11. Other safety issues for discussion requested by the Member States 70

11.1.	Safety related variations of the marketing authorisation.....	70
11.2.	Other requests.....	70
11.2.1.	Teriflunomide (pre-authorisation) - DE/H/7257/001/DC	70

12. Organisational, regulatory and methodological matters 71

12.1.	Mandate and organisation of the PRAC.....	71
12.1.1.	PRAC membership	71
12.1.2.	Vote by proxy	71
12.2.	Coordination with EMA Scientific Committees or CMDh-v	71
12.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	71
12.4.	Cooperation within the EU regulatory network.....	71
12.4.1.	Coronavirus (COVID-19) pandemic - update	71
12.5.	Cooperation with International Regulators.....	71
12.6.	Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee	71
12.7.	PRAC work plan	71

12.7.1.	PRAC work plan 2022.....	71
12.8.	Planning and reporting	72
12.8.1.	Marketing authorisation applications (MAA) forecast for 2022 – planning update dated Q4 2021	72
12.8.2.	European Commission (EC) report on performance of pharmacovigilance tasks - third three-yearly report.....	72
12.9.	Pharmacovigilance audits and inspections	72
12.9.1.	Pharmacovigilance systems and their quality systems	72
12.9.2.	Pharmacovigilance inspections	72
12.9.3.	Pharmacovigilance audits.....	72
12.10.	Periodic safety update reports (PSURs) & Union reference date (EURD) list	72
12.10.1.	Periodic safety update reports	72
12.10.2.	Granularity and Periodicity Advisory Group (GPAG)	72
12.10.3.	PSURs repository	72
12.10.4.	Union reference date list – consultation on the draft list	72
12.11.	Signal management	73
12.11.1.	Signal management – feedback from Signal Management Review Technical (SMART) Working Group	73
12.12.	Adverse drug reactions reporting and additional reporting	73
12.12.1.	Management and reporting of adverse reactions to medicinal products.....	73
12.12.2.	Additional monitoring	73
12.12.3.	List of products under additional monitoring – consultation on the draft list	73
12.13.	EudraVigilance database	73
12.13.1.	Activities related to the confirmation of full functionality	73
12.14.	Risk management plans and effectiveness of risk minimisations	73
12.14.1.	Risk management systems	73
12.14.2.	Tools, educational materials and effectiveness measurement of risk minimisations	73
12.15.	Post-authorisation safety studies (PASS)	73
12.15.1.	Post-authorisation Safety Studies – imposed PASS	73
12.15.2.	Post-authorisation Safety Studies – non-imposed PASS	74
12.16.	Community procedures.....	74
12.16.1.	Referral procedures for safety reasons	74
12.17.	Renewals, conditional renewals, annual reassessments.....	74
12.18.	Risk communication and transparency	74
12.18.1.	Public participation in pharmacovigilance	74
12.18.2.	Safety communication	74
12.19.	Continuous pharmacovigilance	74
12.19.1.	Incident management	74
12.20.	Impact of pharmacovigilance activities	74
12.21.	Others	74

12.21.1.	EMA guidance on companion diagnostics (CDx) – consultation CHMP/CAT assessment report (AR) CDx template - update.....	74
12.21.2.	EU pharmaceutical legislation – revision of Directive 2001/83/EC and Regulation (EC) No 726/2004	74

13.	Any other business	75
------------	---------------------------	-----------

14.	Explanatory notes	76
------------	--------------------------	-----------

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 10-13 January 2022. See January 2022 PRAC minutes (to be published post February 2022 PRAC meeting).

1.2. Agenda of the meeting on 10-13 January 2022

Action: For adoption

1.3. Minutes of the previous meeting on 29 November - 02 December 2021

Action: For adoption

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

3.1.1. Terlipressin (NAP) - EMEA/H/A31/1514

Applicant(s): various

PRAC Rapporteur: To be appointed; PRAC Co-rapporteur: To be appointed

Scope: Review of the benefit-risk balance following notification by Denmark of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Action: For adoption of a list of questions (LoQ)

3.2. Ongoing procedures

None

3.3. Procedures for finalisation

None

3.4. Re-examination procedures¹

None

3.5. Others

None

4. Signals assessment and prioritisation²

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Calcitonin gene-related peptide (CGRP) antagonists: eptinezumab – VYEPTI³, erenumab – AIMOVIG (CAP), fremanezumab – AJOVY (CAP), galcanezumab – EMGALITY (CAP)

Applicant(s): Eli Lilly Nederland B.V. (Emgality), H. Lundbeck A/S (Vyepti), Novartis Europharm Limited (Aimovig), Teva GmbH (Ajoyv)

PRAC Rapporteur: To be appointed

Scope: Signal of Raynaud's phenomenon

Action: For adoption of PRAC recommendation

EPITT 19766 – New signal

Lead Member State(s): FI, NL

¹ Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC

² Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

³ Pending European Commission decision

4.1.2. Osimertinib – TAGRISSO (CAP)

Applicant: AstraZeneca AB

PRAC Rapporteur: Menno van der Elst

Scope: Signal of aplastic anaemia

Action: For adoption of PRAC recommendation

EPITT 19769 – New signal

Lead Member State(s): NL

4.1.3. Roxadustat – EVRENZO (CAP)

Applicant: Astellas Pharma Europe

PRAC Rapporteur: Marek Juracka

Scope: Signal of central hypothyroidism

Action: For adoption of PRAC recommendation

EPITT 19757 – New signal

Lead Member State(s): SK

4.2. New signals detected from other sources

4.2.1. Human normal immunoglobulin⁴ – FLEBOGAMMA DIF (CAP), KIOVIG (CAP), PRIVIGEN (CAP); NAP

Applicant(s): Baxter AG (Kiovig), CSL Behring GmbH (Privigen), Instituto Grifols, S.A. (Flebogamma DIF), various

PRAC Rapporteur: To be appointed

Scope: Signal of thrombocytopenia

Action: For adoption of PRAC recommendation

EPITT 19764 – New signal

Lead Member State(s): DE

4.3. Signals follow-up and prioritisation

4.3.1. Durvalumab – IMFINZI (CAP) - EMEA/H/C/004771/SDA/009

Applicant: AstraZeneca AB

PRAC Rapporteur: David Olsen

Scope: Signal of arthralgia

⁴ For intravenous use only

Action: For adoption of PRAC recommendation

EPITT 19709 – Follow-up to September 2021⁵

4.3.2. [Coronavirus \(COVID-19\) mRNA⁶ vaccine \(nucleoside-modified\) - SPIKEVAX \(CAP\) - EMEA/H/C/005791/SDA/052](#)

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Hans Christian Siersted

Scope: Signal of capillary leak syndrome

Action: For adoption of PRAC recommendation

EPITT 19743 – Follow-up to November 2021⁷

4.3.3. [Pregabalin – LYRICA \(CAP\); NAP - EMEA/H/C/000546/SDA/055](#)

Applicant(s): Upjohn EESV, various

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Signal of toxic epidermal necrolysis

Action: For adoption of PRAC recommendation

EPITT 19723 – Follow-up to September 2021⁸

4.3.4. [Tocilizumab – ROACTEMRA \(CAP\) - EMEA/H/C/000955/SDA/059](#)

Applicant: Roche Registration GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Signal of sarcoidosis

Action: For adoption of PRAC recommendation

EPITT 18860 – Follow-up to September 2021⁹

4.4. **Variation procedure(s) resulting from signal evaluation**

4.4.1. [Coronavirus \(COVID-19\) vaccine \(ChAdOx1-S \[recombinant\]\) - VAXZEVRIA \(CAP\) - EMEA/H/C/005675/II/0055](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: Update of section 4.4 of the SmPC in order to update the warning on thrombosis with thrombocytopenia syndrome (TTS) to indicate that the frequency after the second dose

⁵ Held 30 August – 02 September 2021

⁶ Messenger ribonucleic acid

⁷ Held 25-28 October 2021

⁸ Held 30 August – 02 September 2021

⁹ Held 30 August – 02 September 2021

is lower than after the first dose based on post-marketing data

Action: For adoption of PRAC Assessment Report

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Amifampridine - EMEA/H/C/005839

Scope: Treatment of Lambert-Eaton myasthenic syndrome

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Budesonide, micronised - EMEA/H/C/005653, Orphan

Applicant: Calliditas Therapeutics AB, Hybrid

Scope: Treatment of primary immunoglobulin A (IgA) nephropathy

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Capmatinib - EMEA/H/C/004845

Scope: Treatment of non-small cell lung cancer (NSCLC)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Dimethyl fumarate - EMEA/H/C/006039

Scope: Treatment of multiple sclerosis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. Dimethyl fumarate - EMEA/H/C/005956

Scope: Treatment of multiple sclerosis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Dimethyl fumarate - EMEA/H/C/005955

Scope: Treatment of multiple sclerosis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. Dimethyl fumarate - EMEA/H/C/006042

Scope: Treatment of multiple sclerosis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. [Ganaxolone - EMEA/H/C/005825, Orphan](#)

Applicant: Marinus Pharmaceuticals Emerald Limited

Scope (accelerated assessment): Treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.9. [Insulin aspart - EMEA/H/C/005635](#)

Scope: Treatment of diabetes mellitus

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.10. [Leuprorelin - EMEA/H/C/005034](#)

Scope: Treatment of hormone dependent advanced prostate cancer

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.11. [Mosunetuzumab - EMEA/H/C/005680, Orphan](#)

Applicant: Roche Registration GmbH

Scope (accelerated assessment): Treatment of refractory follicular lymphoma (FL)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.12. [PF-07321332, ritonavir - EMEA/H/C/005973](#)

Scope: Treatment of coronavirus disease 2019 (COVID-19)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. **Medicines in the post-authorisation phase – PRAC-led procedures**

5.2.1. [Acalabrutinib - CALQUENCE \(CAP\) - EMEA/H/C/005299/II/0011](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Željana Margan Koletić

Scope: Submission of an updated RMP (version 3) in order to add hepatotoxicity as an important potential risk to the list of safety concerns

Action: For adoption of PRAC Assessment Report

5.2.2. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/II/0029

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of an updated RMP (version 2.4) in order to reclassify the important potential risk of venous thromboembolism (VTE) as an important identified risk as an outcome of post-authorisation measure MEA 32 finalised in October 2021, to add clinical trial VAC31518COV3003: a randomized, double-blind, phase 3 study to evaluate 6 dose levels of COVID-19 Vaccine Janssen (Ad26.COV2.S) administered as a two-dose schedule in healthy adults and to update study VAC18193RSV2008: a randomized, observer blind, phase 1 study to evaluate innate and proinflammatory responses of an Ad26.RSV.preF based vaccine, Ad26.COV2.S vaccine and Ad26.ZEBOV vaccine in adults aged 18 to 59 years as additional pharmacovigilance activities to further characterize the important identified risks of thrombosis with thrombocytopenia syndrome (TTS), immune thrombocytopenia (ITP), and VTE, and the important potential risk thrombocytopenia (excluding ITP and TTS) as an outcome of post-authorisation measure MEA 14.4 (fifth monthly summary safety report (MSSR)) finalised in September 2021. In addition, the MAH took the opportunity to include other minor updates in the RMP

Action: For adoption of PRAC Assessment Report

5.2.3. Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0020

Applicant: Sandoz GmbH

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of an updated RMP (version 3.0) to remove the German registry Rheumatoide Arthritis: Beobachtung der Biologika-Therapie (RABBIT) registry as an additional pharmacovigilance activity in alignment with the RMP of the reference product and to remove the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) registry as an additional pharmacovigilance activity

Action: For adoption of PRAC Assessment Report

5.2.4. Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/II/0026, Orphan

Applicant: Akcea Therapeutics Ireland Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of an updated RMP (version 3.0) to remove carcinogenicity in rats as missing information and to add a targeted questionnaire as routine pharmacovigilance measure and a patient alert card as additional risk minimisation for liver transplant rejection. In addition, the RMP is updated to add 'injection site reactions' and 'immunogenicity' as risks not considered important for inclusion in the list of safety concerns (S.VII.1.1) and to update the patient alert card with additional warnings on hepatic monitoring and ocular toxicity. The MAH took the opportunity to include further minor updates to the RMP

Action: For adoption of PRAC Assessment Report

5.2.5. Mercaptamine - CYSTADROPS (CAP) - EMEA/H/C/003769/II/0023, Orphan

Applicant: Recordati Rare Diseases

PRAC Rapporteur: Eva Segovia

Scope: Submission of an updated RMP (version 1.4) in order to bring it in line with revision 2 of GVP module V on 'Risk management systems' and to remove 'patients with other ocular co-morbidities' and 'patients receiving concomitant treatment with ophthalmic products containing benzalkonium chloride' as missing information from the list of safety concerns

Action: For adoption of PRAC Assessment Report

5.2.6. Nintedanib - OFEV (CAP) - EMEA/H/C/003821/II/0046

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Submission of an updated RMP (version 11.0) in line with the outcome of the renewal procedure R/0025 finalised in May 2019 to remove the following safety concerns: 1) important identified risks: diarrhoea, liver enzyme and bilirubin elevations including drug-induced liver injury (DILI), bleeding, myocardial infarction; 2) important potential risks: venous thromboembolism, arterial thromboembolism excluding myocardial infarction, perforation, hepatic failure, treatment of pregnant women and teratogenicity, cardiac failure; 3) missing information: treatment of patients with moderate or severe hepatic impairment (Child Pugh B/C), treatment of black patients, treatment of patients with healing wounds, treatment of patients with severe renal impairment or end-stage renal disease, treatment of patients receiving full-dose therapeutic anticoagulation and treatment of breastfeeding women. In addition, the anatomical therapeutic chemical (ATC) code and post-marketing exposure are updated

Action: For adoption of PRAC Assessment Report

5.2.7. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/WS2185/0041; NEPARVIS (CAP) - EMEA/H/C/004343/WS2185/0039

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Submission of an updated RMP (version 3.0) as requested in the outcome of variation WS1830 completed in November 2020. In addition, the following changes have been introduced: 1) change to the agreed milestone for study CLCZ696B2320 (listed as a category 3 study in the RMP): a multicentre, randomized, double-blind, active-controlled study to evaluate the effects of sacubitril/valsartan (LCZ696) compared to valsartan on cognitive function as assessed by comprehensive neurocognitive battery and brain amyloid plaque deposition as assessed by positron emission tomography (PET) imaging in patients with chronic heart failure with preserved ejection fraction; 2) update the date for the submission of the final report for study CLCZ696B2320 from 'Q1 2022' to 'Q1 2023'; 3) update of the presentation of important identified risks and important potential risks; 4) updated exposure and post-marketing data provided for the data lock point of PSUR#9 (31 July 2021)

Action: For adoption of PRAC Assessment Report

5.2.8. [Temozolomide - TEMODAL \(CAP\) - EMEA/H/C/000229/II/0095](#)

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Martin Huber

Scope: Submission of an updated RMP (version 6.1) to bring it in line with revision 2 of GVP module V on 'Risk management systems'. As a consequence, all safety concerns (important identified risks, important potential risks and missing information) are removed

Action: For adoption of PRAC Assessment Report

5.2.9. [Tozinameran - COMIRNATY \(CAP\) - EMEA/H/C/005735/II/0087](#)

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Submission of an updated RMP (version 2.6) to include data from the booster/third dose, including data in patients who have undergone a solid organ transplantation, following the outcome of procedures II/0062 (third dose in immunocompromise as part of the primary vaccination) and II/0067 (booster dose) finalised in October 2021. The MAH took the opportunity to update the RMP regarding the discontinuation of enrolment in study C4591015: a phase 2/3 study to evaluate the safety, tolerability, and immunogenicity in healthy pregnant women 18 years of age and older and the final clinical study report (CSR) milestones

Action: For adoption of PRAC Assessment Report

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. [Alemtuzumab - LEMTRADA \(CAP\) - EMEA/H/C/003718/II/0038](#)

Applicant: Sanofi Belgium

PRAC Rapporteur: Anette Kirstine Stark

Scope: Update of sections 4.4 and 4.8 of the SmPC to add adult onset Still's disease (AOSD) to the list of adverse drug reactions (ADRs) with a frequency not known, based on a signal validated during a routine pharmacovigilance surveillance. The package leaflet is updated accordingly. The MAH took the opportunity to update the list of local representatives in the package leaflet. The RMP (version 9.0) is updated accordingly and reflect the removal of study OBS13436: International Lemtrada (alemtuzumab) pregnancy exposure cohort in multiple sclerosis (pregnancy registry)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. [Brigatinib - ALUNBRIG \(CAP\) - EMEA/H/C/004248/II/0037](#)

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study AP26113-13-301 (listed as a post-authorisation efficacy study (PAES) in Annex II): a randomised, open-label, multicentre phase 3 study comparing brigatinib versus crizotinib in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not previously received ALK-directed therapy. The RMP (version 5.4) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Brivaracetam - BRIVIACT (CAP) - EMEA/H/C/003898/II/0032/G

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Adam Przybylkowski

Scope: Grouped variations consisting of: 1) extension of indication to include patients from 1 month to 4 years of age for treatment with Briviact (brivaracetam). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The RMP (version 8.0) is updated accordingly. Furthermore, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.2). The MAH took the opportunity to implement minor editorial updates; 2) extension of the shelf life after the first opening of Briviact (brivaracetam) oral solution (supported by real time data); 3) addition of a 1 mL oral syringe and its adaptor for the paediatric population. The package leaflet and labelling are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Caplacizumab - CABLIVI (CAP) - EMEA/H/C/004426/II/0035, Orphan

Applicant: Ablynx NV

PRAC Rapporteur: Jan Neuhauser

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on increased risk of bleeding and add blood and lymphatic system disorders to the list of adverse drug reactions (ADRs) with a frequency not known based on a safety evaluation report. The package leaflet and the RMP (version 2.0) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/II/0020

Applicant: Merck Europe B.V.

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Update of sections 4.4 and 4.8 of the SmPC to add liver injury as a warning and as an undesirable effect with a frequency 'uncommon' based on a review of post-approval data in MAH's safety database, non-clinical and clinical trial data and scientific literature on cladribine and liver injury and epidemiological data on hepatic injury in multiple sclerosis (MS)). The package leaflet is updated accordingly. This includes a proposal for a direct healthcare professional communication (DHPC) and communication plan developed to

inform of the risk of serious liver injury and new recommendations about liver function monitoring. The RMP (version 1.7) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. [Delamanid - DELTYBA \(CAP\) - EMEA/H/C/002552/II/0053, Orphan](#)

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Laurence de Fays

Scope: Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs) following the development of an improved methodology to identify relevant ADRs likely attributable to delamanid. The package leaflet and the RMP (version 3.6) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.7. [Dimethyl fumarate - TECFIDERA \(CAP\) - EMEA/H/C/002601/II/0069/G](#)

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Grouped variations consisting of: 1) update of section 4.8 of the SmPC in order to add rhinorrhoea to the list of adverse drug reactions (ADRs) with a frequency not known based on a systematic review of information from clinical and non-clinical studies, post-marketing data and scientific literature. The package leaflet is updated accordingly; 2) update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 109MS303 (ENDORSE) (listed as a category 3 study in the RMP): a dose-blind, multicentre, extension study to determine the long-term safety and efficacy of two doses of dimethyl fumarate (BG00012) monotherapy in subjects with relapsing-remitting multiple sclerosis. The RMP (version 11.1) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.8. [Dimethyl fumarate - TECFIDERA \(CAP\) - EMEA/H/C/002601/II/0073](#)

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Extension of indication to include treatment of relapsing remitting multiple sclerosis (RRMS) in paediatrics patients from 10 years of age and over based on results from study 109MS306: an open-label, randomized, multicentre, multiple-dose, active-controlled, parallel-group, efficacy and safety study of dimethyl fumarate in children from 10 to less than 18 years of age with RRMS with optional open-label extension. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.3 of the SmPC are updated. The package leaflet and the RMP (version 11.4) is updated in accordance. The MAH requested an extension of the market protection of one additional year in line with the guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in accordance with Article 14(11) of Regulation (EC) 726/2004

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0027

Applicant: Roche Registration GmbH

PRAC Rapporteur: Amelia Cupelli

Scope: Extension of indication to include treatment of adult and paediatric patients with haemophilia A without factor VIII (FVIII) inhibitors who have mild or moderate disease for whom prophylaxis is clinically indicated. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 4.2 of the SmPC is updated to make clearer that the maintenance dose for Hemlibra (emicizumab) applies from week 5 of dosing. The package leaflet and the RMP (version 4.0) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Eptacog alfa (activated) - NOVOSEVEN (CAP) - EMEA/H/C/000074/II/0116

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include treatment of severe postpartum haemorrhage for NovoSeven (eptacog alfa). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 8.0) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. Etanercept - ENBREL (CAP) - EMEA/H/C/000262/II/0246

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Eva Segovia

Scope: Update of section 5.1 of the SmPC in order to update clinical information based on final results obtained from the clinical paediatric study B1801023 (CLIPPER 2): an open label extension study to assess the long term safety of etanercept in children and adolescents with extended oligoarticular juvenile idiopathic arthritis, enthesitis related arthritis, or psoriatic arthritis who were previously enrolled in protocol 0881A1 3338 WW(B1801014). The RMP (version 7.5) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. Galsulfase - NAGLAZYME (CAP) - EMEA/H/C/000640/II/0086

Applicant: BioMarin International Limited

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Submission of the final report from the mucopolysaccharidosis (MPS VI clinical surveillance programme (CSP) (listed as a specific obligation (SOB002) in Annex II): an observational CSP to characterise the natural progression of MPS VI; to evaluate the long-term safety and efficacy data from Naglazyme (galsulfase) treatment; to collect information on the effect of Naglazyme (galsulfase) treatment on lactation, growth and development of infants of Naglazyme (galsulfase) treated mothers and to evaluate the effects of Naglazyme (galsulfase) treatment on children under 5 years of age. The RMP (version 6.4) is updated

accordingly to remove gastrointestinal haemorrhage, hepatic impairment and thrombocytopenia from the list of important potential risks

Action: For adoption of PRAC Assessment Report

5.3.13. Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/II/0006, PRIME, Orphan

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.8 of the SmPC to add 'blood homocysteine increase' as a new adverse drug reaction (ADR) and update of section 4.4 of the SmPC to add a related warning. The package leaflet and the RMP (version 1.1) are updated accordingly. In addition, the MAH took the opportunity to make editorial changes to the product information and to update the local representative details for Malta and Cyprus

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Guselkumab - TREMFYA (CAP) - EMEA/H/C/004271/II/0031

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of sections 4.8 and 5.1 of the SmPC based on 2-year data from study CNTO1959PSA3002: a phase 3, multicentre, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of guselkumab administered subcutaneously in subjects with active psoriatic arthritis. The RMP (version 8.2) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Ibrutinib - IMBRUVICA (CAP) - EMEA/H/C/003791/II/0069

Applicant: Janssen-Cilag International NV

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Update of section 4.4 of the SmPC to include information on fatal and serious cardiac arrhythmias and cardiac failure, relevant warnings and periodical monitoring of patients- following a safety assessment for increased risk of sudden death/cardiac death with the use of ibrutinib. The MAH took the opportunity to correct typographical errors throughout the product information. The package leaflet and the RMP (version 11) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.16. Idcabtagene vicleucel - ABECMA (CAP) - EMEA/H/C/004662/II/0010, PRIME, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP¹⁰

PRAC Rapporteur: Annika Folin

¹⁰ Advanced therapy medicinal product

Scope: Update of section 5.1 of the SmPC in order to update efficacy information based on 24 month follow up data from the pivotal study submitted during the initial procedure, namely study BB2121-MM-001 (listed as a specific obligation in Annex II and in the RMP): a phase 2, multicentre study to determine the efficacy and safety of idecabtagene vicleucel (bb2121) in subjects with relapsed and refractory multiple myeloma. Annex II and the RMP (version 1.1) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.17. [Lacosamide - LACOSAMIDE UCB \(CAP\) - EMEA/H/C/005243/WS2049/0009/G;](#) [VIMPAT \(CAP\) - EMEA/H/C/000863/WS2049/0091/G](#)

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Grouped applications consisting of: 1) extension of indication to include patients from 1 month to 4 years of age for treatment of partial-onset seizures with or without secondary generalisation as monotherapy and adjunctive therapy. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The RMP (version 16.0) is updated accordingly; 2) change of a measuring or administration device; 3) extension of the shelf-life of the finished product. The package leaflet and labelling are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. [Luspatercept - REBLOZYL \(CAP\) - EMEA/H/C/004444/II/0009, Orphan](#)

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Laurence de Fays

Scope: Extension of indication in β -thalassaemia to include adult patients with non-transfusion dependent β -thalassaemia (NTDT) for Reblozyl (luspatercept). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 1.1) are updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. [Olaparib - LYNPARZA \(CAP\) - EMEA/H/C/003726/II/0051/G](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Amelia Cupelli

Scope: Extension of indication to include adjuvant treatment of breast cancer for Lynparza (for tablets). As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. In addition, section 4.8 of the SmPC for Lynparza (olaparib) hard capsules is revised based on the updated safety data analysis. The package leaflet and the RMP (version 23) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0117

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include a new indication in combination with chemotherapy with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 38.1) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Ponatinib - ICLUSIG (CAP) - EMEA/H/C/002695/II/0061, Orphan

Applicant: Incyte Biosciences Distribution B.V.

PRAC Rapporteur: Annika Folin

Scope: Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on results from OPTIC study (AP24534-14-203) (listed as a specific obligation (SOB002) in Annex II): a randomised, open-label, phase 2 trial of ponatinib in patients with chronic myeloid leukaemia to characterise the efficacy and safety of ponatinib over a range of doses. The package leaflet and the RMP (version 21.0) are updated accordingly. The RMP (version 21.0) is updated as a response to the request for supplementary information (RSI)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Secukinumab - COSENTYX (CAP) - EMEA/H/C/003729/II/0079

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Eva Segovia

Scope: Extension of indication to include treatment of juvenile idiopathic arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 10.0) are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Semaglutide - OZEMPIC (CAP) - EMEA/H/C/004174/WS2141/0024; RYBELSUS (CAP) - EMEA/H/C/004953/WS2141/0018

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Annika Folin

Scope: Submission of the final report from study NN9535-4386 (SUSTAIN-11) (listed as a category 3 study in the RMP): a 52-week, multicentre, multinational, open-label, active controlled, two armed, parallel, randomised trial undertaken to investigate the effect on glycaemic control, body weight, safety and health-related quality of life of once-weekly semaglutide subcutaneous (sc) vs insulin aspart three times daily, both as add-on to metformin and optimised insulin glargine U100 treatment in subjects with inadequately

controlled type 2 diabetes mellitus (T2DM). The RMP (version 7.0) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. Setmelanotide - IMCIVREE (CAP) - EMEA/H/C/005089/II/0002/G, PRIME, Orphan

Applicant: Rhythm Pharmaceuticals Netherlands B.V.

PRAC Rapporteur: Marek Juracka

Scope: Grouped variations consisting of: 1) addition of a new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and the RMP (version 1.0) are updated accordingly; 2) addition of a new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Alström syndrome (AS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated accordingly. The package leaflet and the RMP (version 1.0) are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Tagraxofusp - ELZONRIS (CAP) - EMEA/H/C/005031/II/0009, Orphan

Applicant: Stemline Therapeutics B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Submission of the final report from study 20255431 (CRL-263114) (listed as a category 3 study in the RMP): a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions - a characterisation of fixed choroid plexus samples from primate study MPI-2231-007 by immunohistochemistry with diphtheria toxin (DT), interleukin-3 receptor (CD123), interleukin-3 (IL-3) and immunoglobulin G (IgG) (in fulfilment of MEA 002). The RMP (version 2.0) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/II/0012

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen for Enhertu (trastuzumab deruxtecan) based on final results from: 1) study DS8201-A-J202 (DESTINY Gastric01): a phase 2, multicentre, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma; 2) study DS8201-A-U205 (DESTINY Gastric02): a phase 2, open-label, single-arm trial of trastuzumab deruxtecan (DS 8201a) in HER2-positive, unresectable or metastatic gastric or GEJ adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP

(version 1.1) are updated accordingly. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/X/0012/G

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Grouped applications consisting of: 1) extension application to add a new strength (45 mg) of the prolonged-release tablets; 2) include the treatment of adults with moderately to severely active ulcerative colitis who had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet, labelling and the RMP (version 6.) are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Afamelanotide - SCENESSE (CAP) - PSUSA/00010314/202106

Applicant: Clinuvel Europe Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.2. Alpelisib - PIQRAY (CAP) - PSUSA/00010871/202105

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.3. Angiotensin II - GIAPREZA (CAP) - PSUSA/00010785/202106

Applicant: Paion Deutschland GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.4. Atidarsagene autotemcel - LIBMELDY (CAP) - PSUSA/00010899/202106

Applicant: Orchard Therapeutics (Netherlands) BV, ATMP¹¹

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.5. Azacitidine - VIDAZA (CAP) - PSUSA/00000274/202105

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.6. Berotralstat - ORLADEYO (CAP) - PSUSA/00010930/202106

Applicant: BioCryst Ireland Limited

PRAC Rapporteur: Julia Pallos

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.7. Betibeglogene autotemcel - ZYNTEGLO (CAP) - PSUSA/00010769/202105

Applicant: bluebird bio (Netherlands) B.V., ATMP¹²

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.8. Binimetinib - MEKTOVI (CAP) - PSUSA/00010717/202106

Applicant: Pierre Fabre Medicament

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

¹¹ Advanced therapy medicinal product

¹² Advanced therapy medicinal product

6.1.9. Bromfenac - YELLOX (CAP) - PSUSA/00000436/202105

Applicant: Bausch Health Ireland Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.10. Buprenorphine¹³ - SIXMO (CAP) - PSUSA/00010778/202105

Applicant: L. Molteni & C. dei Fratelli Alitti Societa di Esercizio S.p.A.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.11. Cannabidiol¹⁴ - EPIDYOLEX (CAP) - PSUSA/00010798/202106

Applicant: GW Pharma (International) B.V.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.12. Cholera vaccine, oral, live - VAXCHORA (CAP) - PSUSA/00010862/202106

Applicant: Emergent Netherlands B.V.

PRAC Rapporteur: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.13. Coronavirus (COVID-19) mRNA¹⁵ vaccine (nucleoside-modified) - SPIKEVAX (CAP) - PSUSA/00010897/202106

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Hans Christian Siersted

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

¹³ Implant(s) only

¹⁴ Centrally authorised product(s) only

¹⁵ Messenger ribonucleic acid

6.1.14. [Coronavirus \(COVID-19\) vaccine \(ChAdOx1-S \[recombinant\]\) - VAXZEVRIA \(CAP\) - PSUSA/00010912/202106](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.15. [Crisaborole - STAQUIS \(CAP\) - PSUSA/00010842/202106](#)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Eva Segovia

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.16. [Dasatinib - SPRYCEL \(CAP\) - PSUSA/00000935/202106](#)

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.17. [Delafloxacin - QUOFENIX \(CAP\) - PSUSA/00010822/202106](#)

Applicant: A. Menarini Industrie Farmaceutiche Riunite s.r.l.

PRAC Rapporteur: Željana Margan Koletić

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.18. [Dengue tetravalent vaccine \(live, attenuated\) - DENGVAXIA \(CAP\) - PSUSA/00010740/202106](#)

Applicant: Sanofi Pasteur

PRAC Rapporteur: Sonja Hrabcik

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.19. [Efmoctocog alfa - ELOCTA \(CAP\) - PSUSA/00010451/202106](#)

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Sonja Hrabcik

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.20. Encorafenib - BRAFTOVI (CAP) - PSUSA/00010719/202106

Applicant: Pierre Fabre Medicament

PRAC Rapporteur: Rugile Pilviniene

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.21. Entrectinib - ROZLYTREK (CAP) - PSUSA/00010874/202106

Applicant: Roche Registration GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.22. Fenfluramine - FINTEPLA (CAP) - PSUSA/00010907/202106

Applicant: Zogenix ROI Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.23. Fluticasone furoate, vilanterol - RELVAR ELLIPTA (CAP); REVINTY ELLIPTA (CAP) - PSUSA/00010099/202105

Applicant(s): GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.24. Formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - TRIxEO AEROSPHERE (CAP) - PSUSA/00010908/202106

Applicant: AstraZeneca AB

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.25. Galsulfase - NAGLAZYME (CAP) - PSUSA/00001515/202105

Applicant: BioMarin International Limited

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.26. Glibenclamide¹⁶ - AMGLIDIA (CAP) - PSUSA/00010690/202105

Applicant: Ammtek

PRAC Rapporteur: Eva Segovia

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.27. Human papillomavirus 9-valent vaccine (recombinant, adsorbed) - GARDASIL 9 (CAP) - PSUSA/00010389/202106

Applicant: MSD Vaccins

PRAC Rapporteur: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.28. Hydroxycarbamide¹⁷ - SIKLOS (CAP); XROMI (CAP) - PSUSA/00001692/202106

Applicant(s): Addmedica S.A.S. (Siklos), Nova Laboratories Ireland Limited (Xromi)

PRAC Rapporteur: Laurence de Fays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.29. Imiglucerase - CEREZYME (CAP) - PSUSA/00001727/202105

Applicant: Genzyme Europe BV

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.30. Inclisiran - LEQVIO (CAP) - PSUSA/00010904/202106

Applicant: Novartis Europharm Limited

¹⁶ Centrally authorised product(s) only

¹⁷ Centrally authorised product(s) only

PRAC Rapporteur: Kimmo Jaakkola
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.31. [Indacaterol, mometasone furoate - ATECTURA BREEZHALER \(CAP\); BEMRIST BREEZHALER \(CAP\) - PSUSA/00010850/202105](#)

Applicant(s): Novartis Europharm Limited
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.32. [Interferon beta-1a¹⁸ - AVONEX \(CAP\) - PSUSA/00010725/202105](#)

Applicant: Biogen Netherlands B.V.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.33. [Interferon beta-1a¹⁹ - REBIF \(CAP\) - PSUSA/00010726/202105](#)

Applicant: Merck Europe B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.34. [Larotrectinib - VITRAKVI \(CAP\) - PSUSA/00010799/202105](#)

Applicant: Bayer AG
PRAC Rapporteur: Rugile Pilviniene
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.35. [Latanoprost, netarsudil - ROCLANDA \(CAP\) - PSUSA/00010905/202106](#)

Applicant: Aerie Pharmaceuticals Ireland Limited
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure

¹⁸ Intramuscular use only
¹⁹ Subcutaneous use only

Action: For adoption of recommendation to CHMP

6.1.36. Levodopa - INBRIJA (CAP) - PSUSA/00107800/202106

Applicant: Acorda Therapeutics Ireland Limited

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.37. Linagliptin - TRAJENTA (CAP); linagliptin, metformin - JENTADUETO (CAP) - PSUSA/00010427/202105

Applicant(s): Boehringer Ingelheim International GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.38. Luspatercept - REBLOZYL (CAP) - PSUSA/00010860/202106

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Laurence de Fays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.39. Migalastat - GALAFOLD (CAP) - PSUSA/00010507/202105

Applicant: Amicus Therapeutics Europe Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.40. Netarsudil - RHOKIINSA (CAP) - PSUSA/00107812/202106

Applicant: Aerie Pharmaceuticals Ireland Limited

PRAC Rapporteur: Eva Segovia

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.41. Nevirapine - VIRAMUNE (CAP) - PSUSA/00002147/202105

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.42. Nonacog beta pegol - REFIXIA (CAP) - PSUSA/00010608/202105

Applicant: Novo Nordisk A/S
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.43. Nusinersen - SPINRAZA (CAP) - PSUSA/00010595/202105

Applicant: Biogen Netherlands B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.44. Obeticholic acid - OCALIVA (CAP) - PSUSA/00010555/202105

Applicant: Intercept Pharma International Limited
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.45. Onasemnogene abeparvovec - ZOLGENSMA (CAP) - PSUSA/00010848/202105

Applicant: Novartis Gene Therapies EU Limited, ATMP²⁰
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CAT and CHMP

6.1.46. Opicapone - ONGENTYS (CAP) - PSUSA/00010516/202106

Applicant: Bial - Portela & C^a, S.A.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

²⁰ Advanced therapy medicinal product

6.1.47. Palivizumab - SYNAGIS (CAP) - PSUSA/00002267/202106

Applicant: AstraZeneca AB

PRAC Rapporteur: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.48. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - ADJUPANRIX (CAP) - PSUSA/00002281/202105

Applicant: GlaxoSmithkline Biologicals SA

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.49. Pegvaliase - PALYNZIQ (CAP) - PSUSA/00010761/202105

Applicant: BioMarin International Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.50. Pentosan polysulfate sodium²¹ - ELMIRON (CAP) - PSUSA/00010614/202106

Applicant: bene-Arzneimittel GmbH

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.51. Pertuzumab - PERJETA (CAP) - PSUSA/00010125/202106

Applicant: Roche Registration GmbH

PRAC Rapporteur: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.52. Pertuzumab, trastuzumab - PHESGO (CAP) - PSUSA/00010906/202106

Applicant: Roche Registration GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

²¹ Centrally authorised product(s) only

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.53. Polatuzumab vedotin - POLIVY (CAP) - PSUSA/00010817/202106

Applicant: Roche Registration GmbH

PRAC Rapporteur: Annika Folin

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.54. Propranolol²² - HEMANGIOL (CAP) - PSUSA/00010250/202104

Applicant: Pierre Fabre Dermatologie

PRAC Rapporteur: Eva Segovia

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.55. Ravulizumab - ULTOMIRIS (CAP) - PSUSA/00010787/202106

Applicant: Alexion Europe SAS

PRAC Rapporteur: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.56. Rilpivirine²³ - EDURANT (CAP) - PSUSA/00009282/202105

Applicant: Janssen-Cilag International NV

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.57. Semaglutide - OZEMPIC (CAP); RYBELSUS (CAP) - PSUSA/00010671/202105

Applicant(s): Novo Nordisk A/S

PRAC Rapporteur: Annika Folin

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

²² Centrally authorised product(s) only

²³ Oral use only

6.1.58. Sildenafil²⁴ - REVATIO (CAP) - PSUSA/00002700/202105

Applicant: Upjohn EESV

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.59. Sofosbuvir, velpatasvir - EPCLUSA (CAP) - PSUSA/00010524/202106

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.60. Sonidegib - ODOMZO (CAP) - PSUSA/00010408/202106

Applicant: Sun Pharmaceutical Industries Europe B.V.

PRAC Rapporteur: Željana Margan Koletić

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.61. Tozinameran - COMIRNATY (CAP) - PSUSA/00010898/202106

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.62. Trametinib - MEKINIST (CAP) - PSUSA/00010262/202105

Applicant: Novartis Europharm Limited

PRAC Rapporteur: David Olsen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.63. Trastuzumab deruxtecan - ENHERTU (CAP) - PSUSA/00010894/202106

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

²⁴ Indicated for the treatment of pulmonary hypertension

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.64. Treosulfan²⁵ - TRECONDI (CAP) - PSUSA/00010777/202106

Applicant: medac Gesellschaft für klinische Spezialpräparate mbH

PRAC Rapporteur: Julia Pallos

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.65. Turoctocog alfa pegol - ESPEROCT (CAP) - PSUSA/00010782/202106

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

6.2.1. Capsaicin - QUTENZA (CAP); NAP - PSUSA/00000533/202105

Applicants: Grunenthal GmbH (Qutenza), various

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.2. Imatinib - GLIVEC (CAP); NAP - PSUSA/00001725/202105

Applicants: Novartis Europharm Limited (Glivec), various

PRAC Rapporteur: Eva Segovia

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.3. Measles, mumps, rubella vaccines (live, attenuated) - M-M-RVAXPRO (CAP); NAP - PSUSA/00001937/202105

Applicants: MSD Vaccins (M-M-RVAXPRO), various

PRAC Rapporteur: Brigitte Keller-Stanislawski

²⁵ Centrally authorised product(s) only

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2.4. [Trepstinil - TREPULMIX \(CAP\); NAP - PSUSA/00003013/202105](#)

Applicants: SciPharm Sarl (Trepulmix), various

PRAC Rapporteur: Zane Neikena

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

6.3.1. [5 fluorouracil, salicylic acid \(NAP\) - PSUSA/00000008/202105](#)

Applicant(s): various

PRAC Lead: Marek Juracka

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.2. [Acipimox \(NAP\) - PSUSA/00000050/202105](#)

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.3. [Amino acid combinations, glucose, triglyceride combinations²⁶, with or without electrolytes, mineral compounds \(NAP\)^{27 28} - PSUSA/00010565/202106](#)

Applicant(s): various

PRAC Lead: Melinda Palfi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

²⁶ E.g. olive oil, soya bean oil, fish oil

²⁷ Intravenous (I.V.) application only

²⁸ Except for the combination with nationally authorised product Numeta

6.3.4. Amino acid combinations, glucose, with or without electrolytes, mineral compounds²⁹ (NAP) - PSUSA/00010566/202106

Applicant(s): various

PRAC Lead: Polona Golmajer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.5. Benazepril, hydrochlorothiazide (NAP) - PSUSA/00000314/202105

Applicant(s): various

PRAC Lead: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.6. Bismuth subcitrate potassium, metronidazole, tetracycline (NAP) - PSUSA/00010199/202105

Applicant(s): various

PRAC Lead: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.7. Cidofovir (NAP) - PSUSA/00010558/202106

Applicant(s): various

PRAC Lead: Rugilė Pilvinienė

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.8. Clevidipine (NAP) - PSUSA/00010288/202105

Applicant(s): various

PRAC Lead: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.9. Daunorubicin (NAP) - PSUSA/00000936/202106

Applicant(s): various

²⁹ Intravenous (I.V.) application only

PRAC Lead: Sonja Hrabcik

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.10. Flunarizine (NAP) - PSUSA/00001416/202105

Applicant(s): various

PRAC Lead: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.11. Goserelin (NAP) - PSUSA/00001562/202105

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.12. Human hemin (NAP) - PSUSA/00001629/202105

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.13. Iodine (¹³¹I) iobenguane (NAP) - PSUSA/00001764/202105

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.14. Lactulose (NAP) - PSUSA/00001821/202105

Applicant(s): various

PRAC Lead: Ilaria Baldelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.15. Lanreotide (NAP) - PSUSA/00001826/202105

Applicant(s): various

PRAC Lead: Zane Neikena

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.16. Levofloxacin, dexamethasone³⁰ (NAP) - PSUSA/00010881/202106

Applicant(s): various

PRAC Lead: Ilaria Baldelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.17. Levonorgestrel³¹ (NAP) - PSUSA/00010828/202105

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.18. Loperamide (NAP); loperamide, simeticone (NAP) - PSUSA/00010665/202105

Applicant(s): various

PRAC Lead: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.19. Milnacipran (NAP) - PSUSA/00002063/202104

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.20. Misoprostol³² (NAP) - PSUSA/00010291/202106

Applicant(s): various

³⁰ Formulation(s) for ocular use only

³¹ All indications except emergency contraception

³² Gastrointestinal indication(s) only

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.21. Misoprostol³³ (NAP) - PSUSA/00010353/202105

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.22. Moxifloxacin³⁴ (NAP) - PSUSA/00002094/202105

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.23. Nadifloxacin (NAP) - PSUSA/00002102/202105

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.24. Olodaterol, tiotropium (NAP) - PSUSA/00010489/202105

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.25. Pamidronate (NAP) - PSUSA/00002269/202105

Applicant(s): various

PRAC Lead: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

³³ Gynaecological indication(s) only - labour induction

³⁴ Topical ophthalmic use only

6.3.26. Paracetamol³⁵ (NAP) - PSUSA/00002311/202105

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.27. Phenylpropanolamine (NAP) - PSUSA/00010483/202106

Applicant(s): various

PRAC Lead: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.28. Pholcodine (NAP) - PSUSA/00002396/202105

Applicant(s): various

PRAC Lead: Nathalie Gault

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.29. Ranitidine (NAP) - PSUSA/00002610/202105

Applicant(s): various

PRAC Lead: Ilaria Baldelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.30. Remifentanil (NAP) - PSUSA/00002617/202105

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.31. Triglyceride combinations³⁶, with or without mineral compounds, electrolytes³⁷ (NAP) - PSUSA/00010648/202106

Applicant(s): various

³⁵ Intravenous (I.V.) formulation only

³⁶ E.g. olive oil, soya bean oil, fish oil

³⁷ Intravenous (I.V.) application only

PRAC Lead: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/LEG 056

Applicant: Upjohn EESV

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Review of Northern Ireland (NI) Health and Social Care Board letter to prescribers on the removal of pregabalin from NI formulary for neuropathic pain, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002511/202101) adopted in September 2021

Action: For adoption of advice to CHMP

6.4.2. Pregabalin - PREGABALIN PFIZER (CAP) - EMEA/H/C/003880/LEG 008

Applicant: Upjohn EESV

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Review of Northern Ireland (NI) Health and Social Care Board letter to prescribers on the removal of pregabalin from NI formulary for neuropathic pain, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002511/202101) adopted in September 2021

Action: For adoption of advice to CHMP

6.4.3. Tenofovir disoproxil - VIREAD (CAP) - EMEA/H/C/000419/LEG 278

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Nathalie Gault

Scope: Detailed analysis of cases of neural tube defects following exposure to tenofovir disoproxil fumarate (TDF) in pregnancy including information on concomitant treatment, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002892/202003) adopted in November 2020

Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Arsenic trioxide - TRISENOX (CAP) - EMEA/H/C/000388/II/0076

Applicant: Teva B.V.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Update of section 4.6 of the SmPC in order to update information on pregnancy and contraception in male patients as requested in the conclusions of the last PSUR single assessment (PSUSA) procedure (PSUSA/00000235/202009) adopted in June 2021. The package leaflet is updated accordingly

Action: For adoption of PRAC Assessment Report

6.5.2. [Baricitinib - OLUMIANT \(CAP\) - EMEA/H/C/004085/II/0031](#)

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Update of section 4.4 of the SmPC in order to add new warnings on major adverse cardiac events (MACE) and amend an existing warning on malignancy and venous thromboembolism (VTE) as requested in the conclusions of the last PSUR single assessment (PSUSA) procedure (PSUSA/00010578/202102) adopted in September 2021 and based on interim results from study I4V-MC-B023: a retrospective observational study to compare baricitinib relative to the standard of care. The package leaflet is updated accordingly. The RMP (version 13.1) has also been submitted. In addition, the MAH has submitted a proposal for a direct healthcare professional communication (DHPC) and communication plan

Action: For adoption of PRAC Assessment Report

6.5.3. [Clofarabine - EVOLTRA \(CAP\) - EMEA/H/C/000613/II/0075](#)

Applicant: Genzyme Europe BV

PRAC Rapporteur: Tiphaine Vaillant

Scope: Update of section 4.6 of the SmPC as requested in the conclusions of the last PSUR single assessment (PSUSA) procedure (PSUSA/00000805/202012) to revise the section on fertility, pregnancy and lactation considering the recommendations of the Safety Working Party (SWP) as reflected in the 'SWP recommendations on the duration of contraception following the end of treatment with a genotoxic drug' and available data. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet and to bring the product information in line with the latest quality review of documents (QRD) template (version 10.2)

Action: For adoption of PRAC Assessment Report

6.5.4. [Coronavirus \(COVID-19\) vaccine \(Ad26.COVID-19, recombinant\) - COVID-19 VACCINE JANSSEN \(CAP\) - EMEA/H/C/005737/II/0035](#)

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of section 4.8 of the SmPC in order to add transverse myelitis to the list of adverse drug reactions (ADRs) with a frequency not known based on the PRAC request from the post-authorisation measures MEA 14.5 and MEA 14.6 (sixth and seventh monthly summary safety reports (MSSR) covering August 2021 and September 2021 respectively) and update of section 4.4 of the SmPC in order to amend the wording on thrombosis and thrombocytopenia syndrome (TTS) as requested in the outcome of post-authorisation

measure MEA 14.5. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to implement an editorial quality review document (QRD) comment in the labelling following completion of variation II/0014 in September 2021

Action: For adoption of PRAC Assessment Report

6.5.5. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0025

Applicant: Roche Registration GmbH

PRAC Rapporteur: Amelia Cupelli

Scope: Update of sections 4.4, 4.8 and 5.1 of the SmPC concerning immunogenicity and loss of efficacy due to anti-emicizumab antibodies as requested in the conclusions of the latest periodic safety update report single assessment (PSUSA) procedure (PSUSA/00010668/202011) adopted in June 2021, together with a review of haemorrhagic cases as requested in the conclusions of the PSUSA procedure (PSUSA/00010668/202005) finalised in January 2021. The RMP (version 3.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

6.5.6. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0080

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Update of section 4.4 of the SmPC in order to amend an existing warning on anxiety-related reactions to add 'numbness' based on the outcome of the ninth monthly summary safety report (MSSR) (MEA 002.8) finalised in October 2021. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information

Action: For adoption of PRAC Assessment Report

6.6. Expedited summary safety reviews³⁸

6.6.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 027.7

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: Eighth expedited summary safety report (SSR) for Vaxzevria (COVID-19 vaccine (ChAdOx1-S [recombinant])) during the coronavirus disease (COVID-19) pandemic

Action: For adoption of PRAC Assessment Report

³⁸ Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)³⁹

7.1.1. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/PSA/S/0075.1

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Tiphaine Vaillant

Scope: MAH's response to PSA/S/0075 [substantial amendment to a protocol previously agreed in December 2017 (PSA/S/0016.2) for study CC-5013-MDS-012: a post-authorisation, non-interventional, retrospective, drug-utilisation study (DUS) to describe the pattern of use of lenalidomide in patients with myelodysplastic syndromes (MDS)] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Parathyroid hormone – NATPAR (CAP) - EMEA/H/C/PSA/S/0053.4

Applicant: Takeda Pharmaceuticals International AG

PRAC Rapporteur: Rhea Fitzgerald

Scope: MAH's response to PSA/S/0053.3 [substantial amendment to a protocol previously agreed in March 2018 (PSA/S/0026) for study PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism): a registry for subjects with chronic hypoparathyroidism to explore physicians advancing disease knowledge in hypoparathyroidism] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.3. Selumetinib - KOSELUGO (CAP) - EMEA/H/C/PSP/S/0095.1

Applicant: AstraZeneca AB

PRAC Rapporteur: Annika Folin

Scope: MAH's response to PSA/S/0053.3 [protocol for a PASS of paediatric patients initiating selumetinib: a multiple-country prospective cohort study] as per the request for supplementary information (RSI) adopted in November 2021

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.4. Tisagenlecleucel - KYMRIA (CAP) - EMEA/H/C/PSA/S/0080

Applicant: Novartis Europharm Limited, ATMP⁴⁰

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Substantial amendment to a protocol previously agreed in November 2019

³⁹ In accordance with Article 107n of Directive 2001/83/EC

⁴⁰ Advanced therapy medicinal product

(PSP/S/0066.3) for registry study CCTL019B2401 to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.5. Valproate⁴¹ (NAP) - EMEA/H/N/PSP/J/0074.4

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

PRAC Rapporteur: Jean-Michel Dogné

Scope: Interim report for a joint observational study to evaluate and identify the best practices for switching of valproate in clinical practice, as required in the outcome of the referral procedure under Article 31 of Directive 2001/83/EC on valproate-containing products completed in February 2018 (EMEA/H/A-31/1454)]

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.6. Valproate⁴² (NAP) - EMEA/H/N/PSA/J/0077

Applicant: Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

PRAC Rapporteur: Jean-Michel Dogné

Scope: Substantial amendment to a protocol previously agreed in July 2020 (PSP/0074.3) for an observational study to evaluate and identify the best practices for switching of valproate in clinical practice

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.7. Voretigene neparvovec - LUXTURNA (CAP) - EMEA/H/C/PSA/S/0081

Applicant: Novartis Europharm Ltd, ATMP⁴³

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Substantial amendment to a protocol previously agreed in March 2021 (PSA/S/0066) for a post-authorisation multicentre, multinational, longitudinal, observational safety registry study to collect long-term safety information associated with voretigene neparvovec (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

⁴¹ Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

⁴² Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

⁴³ Advanced therapy medicinal product

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)⁴⁴

7.2.1. Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/MEA 003.1

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 003.1 [protocol for study CBYL719C2005: a survey among healthcare professionals treating patients with metastatic breast cancer in selected European countries to evaluate their knowledge on management of hyperglycaemia when using Piqray (alpelisib) as included in the educational material] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.2.2. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 004.2

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 004.1 [protocol for study 215162 (listed as a category 3 study in the RMP): a prospective observational cohort study to monitor for hepatotoxicity and regimen discontinuation due to liver related adverse events among patients initiating cabotegravir-containing antiretroviral regimen [final clinical study report (CSR): expected in March 2027]] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.2.3. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 005.2

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 005.1 [protocol for study 215163: a study on pregnancy and neonatal outcomes following prenatal exposure to cabotegravir long acting (CAB LA) – data from the European Pregnancy and Paediatric human immunodeficiency virus (HIV) Cohort Collaboration (EPPICC)] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.2.4. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 006.2

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 006.1 [protocol for study 215325: a study on pregnancy and

⁴⁴ In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

neonatal outcomes following prenatal exposure to cabotegravir – data from the Antiretroviral Pregnancy Registry (APR)] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.2.5. [Coronavirus \(COVID-19\) mRNA⁴⁵ vaccine \(nucleoside-modified\) - SPIKEVAX \(CAP\) - EMEA/H/C/005791/MEA 004.4](#)

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Hans Christian Siersted

Scope: MAH's response to MEA 004.3 [protocol for study mRNA-1273-P904 (study 1) (listed as a category 3 study in the RMP): a post-authorisation active surveillance safety study using secondary data to monitor real-world safety of Spikevax (COVID-19 mRNA-1273 vaccine) in Europe - an enhanced pharmacovigilance study to provide additional evaluation of adverse events of special interest (AESI) and emerging validated safety signals in European populations and electronic database assessment of use in pregnant women [final clinical study report (CSR) expected in December 2023]] as per the request for supplementary information (RSI) adopted in July 2021 together with the first study progress report for study mRNA-1273-P904

Action: For adoption of advice to CHMP

7.2.6. [Isatuximab - SARCLISA \(CAP\) - EMEA/H/C/004977/MEA 002.2](#)

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Eva Segovia

Scope: MAH's response to MEA 002.1 [protocol for study SARSAC09715: a non-interventional PASS survey to evaluate the effectiveness of isatuximab educational materials to minimise the risk of interference for blood typing (minor antigen) (positive indirect Coombs' test)] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.2.7. [Patisiran - ONPATTRO \(CAP\) - EMEA/H/C/004699/MEA 003.2](#)

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Update to a previously agreed protocol and interim study report for study ALN-TTR02-010: patisiran- lipid nanoparticle (LNP) pregnancy surveillance programme (PSP) to collect primary data on pregnant women from the US, the United Kingdom (UK), France, Spain, Italy, Portugal and Germany, and other potential countries, who have been exposed to patisiran during the exposure window, defined as 12 weeks prior to their last menstrual period (LMP), or at any time during pregnancy as well as to collect and analyse information pertaining to pregnancy complications and birth outcomes in women exposed to patisiran

⁴⁵ Messenger ribonucleic acid

during pregnancy

Action: For adoption of advice to CHMP

7.2.8. Ponesimod - PONVORY (CAP) - EMEA/H/C/005163/MEA 001

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Anette Kirstine Stark

Scope: Protocol for study PCSNSP004001 (listed as a category 3 study in the RMP): ponesimod pregnancy outcomes enhanced monitoring (POEM) - pregnancy outcomes programme utilising enhanced pharmacovigilance monitoring to evaluate the potential risk of reproductive and embryofetal toxicity in pregnant women exposed to ponesimod (from initial opinion/marketing authorisation)

Action: For adoption of advice to CHMP

7.2.9. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 001.4

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Substantial amendment to a protocol previously agreed in January 2021 for study P19-633: a post-marketing registry-based prospective cohort study of long-term safety of risankizumab in real world setting in Denmark and Sweden [final study report expected in December 2031] together with a statistical analysis plan (SAP)

Action: For adoption of advice to CHMP

7.2.10. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 002.7

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Substantial amendment to a previously agreed protocol for study CLCZ696B2014 (PASS 1) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to characterise the risk of angioedema and other specific safety events of interest in association with the use of Entresto/Neparvis (sacubitril/valsartan) in adult patients with heart failure [final report expected in Q4 2022] together with a statistical analysis plan (SAP)

Action: For adoption of advice to CHMP

7.2.11. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 002.4

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Substantial amendment to a previously agreed protocol for study CLCZ696B2014 (PASS 1) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to characterise the risk of angioedema and other

specific safety events of interest in association with the use of Entresto/Neparvis (sacubitril/valsartan) in adult patients with heart failure [final report expected in Q4 2022] together with a statistical analysis plan (SAP)

Action: For adoption of advice to CHMP

7.2.12. Somapacitan - SOGROYA (CAP) - EMEA/H/C/005030/MEA 002.1

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 002 [protocol for study NN8640-4515: a multinational, multicentre, prospective, open label, single-arm, observational, non-interventional PASS to investigate long-term safety of somapacitan in adults with growth hormone deficiency (AGHD) under normal clinical practice conditions (from initial marketing authorisation/opinion)] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.2.13. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/MEA 003.1

Applicant: Daiichi Sankyo Europe GmbH

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: MAH's response to MEA 003 [protocol for an EU survey of relevant healthcare professionals on the understanding of key risk minimisation measures pertaining to interstitial lung disease (ILD)/pneumonitis with trastuzumab deruxtecan treatment (from initial marketing authorisation/opinion)] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)⁴⁶

7.3.1. Hydroxyethyl starch (HES) (NAP) - EMEA/H/N/PSR/J/0031

Applicant(s): Fresenius Kabi Deutschland GmbH (Volulyte, Voluven), B. Braun Melsungen AG (Tetraspan, Venofundin)

PRAC Rapporteur: Nathalie Gault

Scope: MAH's response to PSR/J/0031 [results for a joint retrospective, multinational, drug utilisation study (DUS) to assess the non-adherence of physicians in hydroxyethyl starch (HES) accredited hospitals to the approved European product information [regarding indication for use, contraindications and posology (dosage)] for HES 130-containing medicinal products in clinical routine after implementation of a set of risk minimisation measures as required in the outcome of the referral procedure under Article 107i of Directive 2001/83/EC for HES completed in 2018 (EMEA/H/A-107i/1457)] as per the request

⁴⁶ In accordance with Article 107p-q of Directive 2001/83/EC

for supplementary information (RSI) adopted in October 2021

Action: For adoption of recommendation to CMDh (or request for supplementary information (RSI))

7.4. Results of PASS non-imposed in the marketing authorisation(s)⁴⁷

7.4.1. Apremilast - OTEZLA (CAP) - EMEA/H/C/003746/II/0039

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Eva Segovia

Scope: Submission of the final study report (CSR) from the UK Clinical Practice Research Database (CPRD) (listed as a category 3 study in the RMP): an observational study to assess the long-term data of apremilast in patients with psoriasis and psoriatic arthritis. The RMP (version 14.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.2. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0028

Applicant: Roche Registration GmbH

PRAC Rapporteur: Amelia Cupelli

Scope: Submission of the final study report for BO40853 (listed as a category 3 study in the RMP): a survey to prescribers and patients/carers to evaluate awareness, knowledge, and compliance to additional risk minimisation measures. The RMP (version 4.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.3. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0231

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of the final report of the Remicade (infliximab) Anti-Rheumatic Therapy in Sweden (ARTIS) register study. The RMP (version 20.1) is updated accordingly and with revisions agreed in previous procedures

Action: For adoption of PRAC Assessment Report

7.4.4. Influenza vaccine surface antigen inactivated prepared in cell cultures - FLUCELVAX TETRA (CAP) - EMEA/H/C/004814/II/0023

Applicant: Seqirus Netherlands B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

⁴⁷ In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

Scope: Update of section 4.6 of the SmPC in order to update information on pregnancy registry 130_110B (listed as a category 3 study in the RMP) on use in pregnant and breastfeeding women to evaluate pregnancy outcomes. The package leaflet and the RMP (version 3.1) are updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.5. Insulin glargine, lixisenatide - SULIQUA (CAP) - EMEA/H/C/004243/II/0024

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Menno van der Elst

Scope: Submission of the final clinical study report (CSR) of study INSLIC08571 (listed as a category 3 study in the RMP): a survey to evaluate the knowledge and understanding of the key safety messages in the healthcare professional guide and the patient guide (in fulfilment of MEA 002). The RMP (version 6.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.6. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0034

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of the final report from study D3820R00006 (listed as a category 3 study in the RMP): an observational drug utilisation in selected European populations. The RMP (version 7.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.7. Susoctocog alfa - OBIZUR (CAP) - EMEA/H/C/002792/II/0043

Applicant: Baxalta Innovations GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Submission of the final report from study US PASS 241302 (EUPAS36659) (listed as a category 3 study in the RMP): a post-marketing non-interventional safety evaluation of Obizur (susoctocog alfa) in the treatment of bleeding episodes for patients with acquired haemophilia A (AHA) to determine the incidence of therapy-related serious adverse events (SAEs) in patients with AHA who are prescribed and treated with Obizur (susoctocog alfa) in routine clinical practice. The RMP (version 5.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.8. Teriflunomide - AUBAGIO (CAP) - EMEA/H/C/002514/II/0038

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Martin Huber

Scope: Submission of the final study report for study OBS12753 (listed as a category 3 study in the RMP): a prospective cohort study of long-term safety of teriflunomide in

multiple sclerosis patients in Europe. The RMP (version 7.1) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.9. Trastuzumab - ONTRUZANT (CAP) - EMEA/H/C/004323/II/0036

Applicant: Samsung Bioepis NL B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Submission of the final report from clinical study SB3-G31-BC-E (listed as a category 3 study in the RMP): an observational cohort study assessing the long-term cardiac safety (for cardiac safety and survival cohort) and survival (survival only cohort and cardiac safety and survival cohort) in patients who received treatment with trastuzumab. The RMP (version 5.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Acridinium - BRETARIS GENUAIR (CAP) - EMEA/H/C/002706/ANX 001.10

Applicant: AstraZeneca AB

PRAC Rapporteur: Adam Przybylkowski

Scope: MAH's response to ANX 001.9 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of acridinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.5.2. Acridinium - EKLIRA GENUAIR (CAP) - EMEA/H/C/002211/ANX 001.10

Applicant: AstraZeneca AB

PRAC Rapporteur: Adam Przybylkowski

Scope: MAH's response to ANX 001.9 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of acridinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.5.3. [Aclidinium, formoterol fumarate dihydrate - BRIMICA GENUAIR \(CAP\) - EMEA/H/C/003969/ANX 003.7](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Adam Przybylkowski

Scope: MAH's response to ANX 003.6 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of aclidinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.5.4. [Aclidinium, formoterol fumarate dihydrate - DUAKLIR GENUAIR \(CAP\) - EMEA/H/C/003745/ANX 003.7](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Adam Przybylkowski

Scope: MAH's response to ANX 003.6 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of aclidinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.5.5. [Burosumab - CRYSVITA \(CAP\) - EMEA/H/C/004275/MEA 004.3](#)

Applicant: Kyowa Kirin Holdings B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: First interim report for study 2019-36-EU-CRY (EUPAS32190): a non-interventional study in the treatment of children >1 year of age and adolescents with X-linked hypophosphataemia (XLH) to assess the long term safety of Crysvida (burosumab) during routine clinical care using data collected in a European disease registry for XLH [final report expected in December 2028]

Action: For adoption of advice to CHMP

7.5.6. [Cangrelor - KENGREXAL \(CAP\) - EMEA/H/C/003773/MEA 002.4](#)

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Amelia Cupelli

Scope: Second interim report for study DFIDM-1801 (ARCANGELO (itAlian pRospective

study on CANGrELOr)): a multicentre prospective observational study of acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI) who receive cangrelor and transition to either clopidogrel, prasugrel or ticagrelor

Action: For adoption of advice to CHMP

7.5.7. [Cladribine - MAVENCLAD \(CAP\) - EMEA/H/C/004230/MEA 002.2](#)

Applicant: Merck Europe B.V.

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: First interim report for study MS 700568-0002 (listed as a category 3 study in the RMP): a prospective, observational cohort study evaluating the safety profile, in terms of incidence of adverse events of special interest, in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine [final report expected in Q2 2034]

Action: For adoption of advice to CHMP

7.5.8. [Coronavirus \(COVID-19\) vaccine \(ChAdOx1-S \[recombinant\]\) - VAXZEVRIA \(CAP\) - EMEA/H/C/005675/MEA 005.2](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: First interim report for study D8111R00003: a phase 4 non-interventional enhanced active surveillance study of adults vaccinated with Vaxzevria (AZD1222 – COVID-19 vaccine)

Action: For adoption of advice to CHMP

7.5.9. [Coronavirus \(COVID-19\) vaccine \(ChAdOx1-S \[recombinant\]\) - VAXZEVRIA \(CAP\) - EMEA/H/C/005675/MEA 006.2](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: First quarterly report for study C-VIPER: a pregnancy registry of women exposed to Vaxzevria (AZD1222 – COVID-19 vaccine) immediately before or during pregnancy (from initial opinion/marketing authorisation(s) (MA))

Action: For adoption of advice to CHMP

7.5.10. [Coronavirus \(COVID-19\) vaccine \(ChAdOx1-S \[recombinant\]\) - VAXZEVRIA \(CAP\) - EMEA/H/C/005675/MEA 007.3](#)

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: First progress report for study D8111R00006: a post-authorisation/post-marketing observational study using existing secondary health data sources to evaluate the association between exposure to Vaxzevria (AZD1222) and safety concerns

Action: For adoption of advice to CHMP

7.5.11. [Coronavirus \(COVID-19\) mRNA⁴⁸ vaccine \(nucleoside-modified\) - SPIKEVAX \(CAP\) - EMEA/H/C/005791/MEA 003.4](#)

Applicant: Moderna Biotech Spain, S.L.

PRAC Rapporteur: Hans Christian Siersted

Scope: Third Interim report for a study (listed as a category 3 study in the RMP): a post authorisation safety of Spikevax (SARS-CoV-2 mRNA-1273 vaccine) in the US - an enhanced pharmacovigilance study (listed as a category 3 study in the RMP) to provide additional evaluation of adverse events of special interest (AESI) and emerging validated safety signals [final clinical study report (CSR) expected in June 2023] (from initial opinion/marketing authorisation (MA))

Action: For adoption of advice to CHMP

7.5.12. [Ketoconazole - KETOCONAZOLE HRA \(CAP\) - EMEA/H/C/003906/ANX 002.8](#)

Applicant: HRA Pharma Rare Diseases

PRAC Rapporteur: Željana Margan Koletić

Scope: Fourth interim annual report for a prospective, multi-country, observational registry study to collect clinical information on patients with endogenous Cushing's syndrome exposed to ketoconazole using the existing European registry on Cushing's syndrome (ERCUSYN) to assess drug utilisation pattern and to document the safety (e.g. hepatotoxicity, QT prolongation) and effectiveness of ketoconazole

Action: For adoption of advice to CHMP

7.5.13. [Romosozumab - EVENITY \(CAP\) - EMEA/H/C/004465/MEA 001.3](#)

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Second interim report for study OP0005: a European non-interventional PASS to study the adherence to the risk minimisation measures (RMMs) in the product information by estimating the compliance with contraindications and target indication(s) amongst incident romosozumab users, and analysing the utilisation pattern using the EU-adverse drug reactions (EU-ADR) Alliance [final study results expected in March 2026]

Action: For adoption of advice to CHMP

7.5.14. [Romosozumab - EVENITY \(CAP\) - EMEA/H/C/004465/MEA 002.3](#)

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Second interim report for study OP0004: a European non-interventional PASS to

⁴⁸ Messenger ribonucleic acid

evaluate potential differences in terms of serious cardiovascular adverse events between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance [final study results expected in December 2026]

Action: For adoption of advice to CHMP

7.5.15. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.2

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Tiphaine Vaillant

Scope: First interim report for study OP0006: a European non-interventional PASS to evaluate potential differences in terms of serious infection between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance [final study results expected in December 2024]

Action: For adoption of advice to CHMP

7.5.16. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 004.11

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Fourth interim results for study CLCZ696B2015 (PASS 3) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of Entresto/Neparvis (sacubitril/valsartan) [final study report expected in December 2022]

Action: For adoption of advice to CHMP

7.5.17. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 003.8

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: Fourth interim results for study CLCZ696B2015 (PASS 3) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of Entresto/Neparvis (sacubitril/valsartan) [final study report expected in December 2022]

Action: For adoption of advice to CHMP

7.5.18. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 045.7

Applicant: Janssen-Cilag International NV

PRAC Rapporteur: Rhea Fitzgerald

Scope: MAH's response to MEA 045.6 [second interim report for study RRA-20745: an observational PASS to describe the safety of ustekinumab and other Crohn's disease treatments in a cohort of patients with Crohn's disease] as per the request for supplementary information (RSI) adopted in September 2021

Action: For adoption of advice to CHMP

7.6. Others

7.6.1. Cabazitaxel - CABAZITAXEL ACCORD (CAP) - EMEA/H/C/005178/MEA 001.1

Applicant: Accord Healthcare S.L.U.

PRAC Rapporteur: Tiphaine Vaillant

Scope: Second six-monthly review of cases of 'medication error' for cabazitaxel reported during routine signal management activities

Action: For adoption of advice to CHMP

7.6.2. Fentanyl - INSTANYL (CAP) - EMEA/H/C/000959/LEG 028.4

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Tiphaine Vaillant

Scope: Fifth six-monthly update on the development of the child-resistant multi-dose nasal spray DoseGuard as requested in the conclusions of procedure R/0049 finalised in April 2019

Action: For adoption of advice to CHMP

7.6.3. Insulin human - INSUMAN (CAP) - EMEA/H/C/000201/MEA 041.5

Applicant: Sanofi-Aventis Deutschland GmbH

PRAC Rapporteur: Jean-Michel Dogné

Scope: MAH's request of early termination of study HUBIN-C-06380: a European observational cohort of patients with type 1 diabetes treated via intraperitoneal route with Insuman Implantable 400 IU/mL in Medtronic MiniMed implantable pump

Action: For adoption of advice to CHMP

7.6.4. Lopinavir, ritonavir - KALETRA (CAP) - EMEA/H/C/000368/LEG 121.4

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Nathalie Gault

Scope: Fourth annual safety review of the PENTA - European Pregnancy and Paediatric human immunodeficiency virus (HIV) Cohort Collaboration (EPPICC) cohort study conducted in children from 14 days to 2 years of age as regards to chronic exposure to propylene glycol and ethanol and toxicity, medication errors and lack of efficacy/resistance in relation

to potentially suboptimal pharmacokinetic (PK) parameters

Action: For adoption of advice to CHMP

7.7. New Scientific Advice

None

7.8. Ongoing Scientific Advice

None

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

None

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Idebenone - RAXONE (CAP) - EMEA/H/C/003834/S/0029 (with RMP)

Applicant: Santhera Pharmaceuticals (Deutschland) GmbH

PRAC Rapporteur: Amelia Cupelli

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.2. Metreleptin - MYALEPTA (CAP) - EMEA/H/C/004218/S/0023 (without RMP)

Applicant: Amryt Pharmaceuticals DAC

PRAC Rapporteur: Adam Przybylkowski

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.2. Conditional renewals of the marketing authorisation

8.2.1. Andexanet alfa - ONDEXXYA (CAP) - EMEA/H/C/004108/R/0025 (without RMP)

Applicant: Alexion Europe SAS

PRAC Rapporteur: Menno van der Elst

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.2. Bosutinib - BOSULIF (CAP) - EMEA/H/C/002373/R/0051 (without RMP)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.3. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/R/0052 (without RMP)

Applicant: Otsuka Novel Products GmbH

PRAC Rapporteur: Laurence de Fays

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.4. Lorlatinib - LORVIQUA (CAP) - EMEA/H/C/004646/R/0019 (without RMP)

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.5. Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - PANDEMIC INFLUENZA VACCINE H5N1 ASTRAZENECA (CAP) - EMEA/H/C/003963/R/0047 (without RMP)

Applicant: AstraZeneca AB

PRAC Rapporteur: Sonja Hrabcik

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.6. Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/R/0030 (without RMP)

Applicant: Clovis Oncology Ireland Limited

PRAC Rapporteur: Annika Folin

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3. Renewals of the marketing authorisation

8.3.1. Beclometasone, formoterol, glycopyrronium bromide - TRIMBOW (CAP) - EMEA/H/C/004257/R/0025 (without RMP)

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.2. Brodalumab - KYNTHEUM (CAP) - EMEA/H/C/003959/R/0019 (with RMP)

Applicant: LEO Pharma A/S

PRAC Rapporteur: Eva Segovia

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.3. Carglumic acid - UCEDANE (CAP) - EMEA/H/C/004019/R/0011 (without RMP)

Applicant: Eurocept International B.V.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.4. Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/R/0026 (with RMP)

Applicant: Gedeon Richter Plc.

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.5. Cenegermin - OXERVATE (CAP) - EMEA/H/C/004209/R/0037 (with RMP)

Applicant: Dompe farmaceutici S.p.A.

PRAC Rapporteur: Jan Neuhauser

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.6. Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/R/0034 (without RMP)

Applicant: BioMarin International Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.7. Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/R/0053 (with RMP)

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Kimmo Jaakkola

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.8. Efavirenz, emtricitabine, tenofovir disoproxil - EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP) - EMEA/H/C/004250/R/0025 (without RMP)

Applicant: Zentiva k.s.

PRAC Rapporteur: Martin Huber

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.9. Etanercept - ERELZI (CAP) - EMEA/H/C/004192/R/0037 (with RMP)

Applicant: Sandoz GmbH

PRAC Rapporteur: Eva Segovia

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.10. Glecaprevir, pibrentasvir - MAVIRET (CAP) - EMEA/H/C/004430/R/0048 (without RMP)

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.11. Insulin lispro - INSULIN LISPRO SANOFI (CAP) - EMEA/H/C/004303/R/0013 (with RMP)

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Annika Folin

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.12. Osimertinib - TAGRISSO (CAP) - EMEA/H/C/004124/R/0044 (with RMP)

Applicant: AstraZeneca AB

PRAC Rapporteur: Menno van der Elst

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.13. Patiromer - VELTASSA (CAP) - EMEA/H/C/004180/R/0028 (without RMP)

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Kirsti Villikka

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.14. Ribociclib - KISQALI (CAP) - EMEA/H/C/004213/R/0034 (without RMP)

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Anette Kirstine Stark

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States' safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Other requests

11.2.1. Teriflunomide (pre-authorisation) - DE/H/7257/001/DC

Scope: PRAC consultation on the evaluation of an initial marketing authorisation application under the decentralised procedure for a generic teriflunomide-containing medicinal product in order to consider the need for pharmacovigilance activities, on request of Germany.

Action: For adoption of advice to Member States

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

Action: For information

12.1.2. Vote by proxy

None

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Coronavirus (COVID-19) pandemic - update

Action: For discussion

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

12.7.1. PRAC work plan 2022

PRAC lead: Sabine Straus, Martin Huber

Action: For adoption

12.8. Planning and reporting

12.8.1. Marketing authorisation applications (MAA) forecast for 2022 – planning update dated Q4 2021

Action: For discussion

12.8.2. European Commission (EC) report on performance of pharmacovigilance tasks - third three-yearly report

Action: For discussion

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst, Maia Uusküla

Action: For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption

12.11. Signal management

12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

PRAC lead: Menno van der Elst

Action: For discussion

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Management and reporting of adverse reactions to medicinal products

None

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

Action: For adoption

12.13. EudraVigilance database

12.13.1. Activities related to the confirmation of full functionality

None

12.14. Risk management plans and effectiveness of risk minimisations

12.14.1. Risk management systems

None

12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

None

12.21. Others

12.21.1. EMA guidance on companion diagnostics (CDx) – consultation CHMP/CAT assessment report (AR) CDx template - update

Action: For discussion

12.21.2. EU pharmaceutical legislation – revision of Directive 2001/83/EC and Regulation (EC) No 726/2004

PRAC lead: Amelia Cupelli, Maria del Pilar Rayon, Liana Gross-Martirosyan, Martin Huber,

Eva Segovia, Sabine Straus, Menno van der Elst, Ulla Wandel Liminga

Action: For discussion

13. Any other business

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures

(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation

(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.

The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.

The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)

(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.

RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)

(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.

PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)

(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections

(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/